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Abstract
Purpose: The purpose of this work was to investigate the use of pre-calculated Monte Carlo
(MC) ovoid and source-based attenuation-correction factors that would correct a commerciallyavailable brachytherapy treatment planning system (TPS) generated plan in order to account for
any dosimetric effects due to the presence of intracavitary brachytherapy (ICBT) applicators
during treatment delivery.
Methods: A MC model of an ICBT CT-MR compatible ovoid applicator set was confirmed
utilizing radiochromic film (RCF). MC was used to simulate dose distributions resulting from
eight source-dwell-positions within the ICBT applicator. Also, the American Association of
Physicist in Medicine Task Group 43 Report (AAPM TG-43) was utilized to calculate absolute
dose rate around a microSelectron version 2 192Ir source contained in water. With these dose
distributions, a library of ovoid and source-based 3D attenuation-correction factor datasets
characterizing the dosimetric effects of the ICBT applicator was developed. Appropriate
attenuation-correction factors were then applied to correct a brachytherapy TPS-calculated plan.
Several plans with different maximum dwell-time gradients (∇dt) were compared to evaluate the
effectiveness of both correction methods with respect to criteria of acceptability being within +/2% absolute dose or +/- 2 mm distance-to-agreement (DTA).
Results: RCF confirmation measurements from 3 active dwell-positions in a single ovoid agreed
with MC simulated planes with over 96% of points agreeing within 2% or 2 mm DTA. Plans
generated by Oncentra TPS can be corrected utilizing either the ovoid-based or source-based
correction methods to agree with full simulated Monte Carlo datasets to within +/- 2% or +/2mm DTA. Although, dwell-time combinations utilized in this study with a maximum dwelltime gradient above 10% is a threshold for the ovoid- based correction scheme to correct the TG-

ix

43 calculation. The source- based correction method consistently results in 100% agreement
between a corrected plan and the equivalent MC generated plan.
Conclusions: The MC model is sufficient to predict measured RCF dose distributions
accurately. Source- based correction factors can be applied to correct a TG-43 based treatment
plan to match a full MC simulation.

x

Chapter 1 Introduction
1.1 Brachytherapy for the Treatment of Cervical Carcinoma
Intracavitary brachytherapy (ICBT) has an advantage over external beam radiotherapy
(EBRT) for local control because it allows for dose escalation while sparing normal tissue
surrounding the treatment volume. Cervical cancer treatment is typically a combination of
EBRT and ICBT. EBRT is generally delivered first in order to reduce the volume of the primary
disease before ICBT as well as to control the spread of disease at the periphery of the tumor bed.
Unlike in EBRT, where radiation is directed at the disease from outside the body, ICBT involves
placing a radioactive source within close proximity or inside the target tissue. Due to the inverse
square law, i.e. the exposure due to a source is inversely proportional to the square of the
distance from the source; the high-dose region delivered from a radioactive source is localized
and has a very steep dose gradient.
The current ICBT cervical technique is to remotely afterload radioactive sources into a
tandem and ovoids once they have been placed in the uterine canal. A photo of Nucletron’s
computed tomography, magnetic resonance (CT-MR) compatible tandem and ovoids is shown in
Figure 1.1. During an ICBT treatment, the radioactive source is remotely after loaded into the
applicator and the source steps to varying positions (i.e., 5 mm back) within the applicator shaft.
The process of moving a single source to multiple positions in the applicator simulates a singlelong source in the applicator. The design of an applicator allows delivery of the radioactive
source and a specific dose distribution around the disease.
A tandem is a hollow tube and is inserted directly through the cervical opening into the
endometrial cavity (inner uterine lining). Although only 5 cm of the tandem is placed in the
uterus, tandems are approximately 25 cm in length and are available in varying curvatures (i.e.
15º, 30º, 45º) to accommodate variations in disease location and patient anatomies. The ovoids
1

are positioned lateral to the cervical opening on opposite sides within the vaginal fornices. In
addition to the ICBT technique, a “packing” procedure holds the ovoids relatively stationary
post-insertion and displaces the rectum and bladder away from the high dose volume. “Packing”
refers to inserting gauze around the ovoids in the patient’s anterior and posterior directions. This
additional procedure takes advantage of the distortable characteristic of the vagina and the
inverse-square dose falloff applicable with ICBT.

Figure 1.1: CT-MR Fletcher applicator set.

1.2 Prescription Methodologies for Gynecological ICBT
Dosimetry systems for brachytherapy consist of a set of rules which, when followed,
would deliver dose in a clinically desirable distribution to a designated anatomical region. These
guidelines specify treatment delivery parameters in terms of dose, time, and source position in an
attempt to deliver a prescribed dose in a reproducible manner. Dosimetry systems also provide
standardization for treatments which allow inter-institutional comparison of results.
1.2.1 Manchester System
The Manchester system, developed by Ralston Paterson, M.D. and Herbert Parker, Ph.D.
at Manchester Hospital, defines four points at which delivered dose rates are to be considered:
point A, point B, a bladder point, and a rectum point. The duration of the implant is based on the
2

dose rate calculated at point A, although the dose at the other points are recorded and evaluated
during the treatment planning process. As illustrated in Figure 1.2, the left and right point A’s
were defined as 2 cm superior and lateral to the vaginal fornices. Point B was defined 3 cm
lateral to the left and right point A’s. Ideally, Point A represents an anatomical location where
the uterine vessels cross the ureter, and point B represents the location of lymph nodes. Within
the Manchester system, the locations of prescription points are a function of source orientations
and not specified directly in terms of a patient’s anatomical structures. For an ICBT cervical
treatment, the delivered dose distribution ideally resembles a “pear shape” when viewed in the
anterior-posterior (AP) plane. In some patient instances, this method of defining prescribed
doses to a specific point risks under dosage of a large cervical tumor or over dosage of small
tumors [1].

Figure 1.2: Anatomy illustration to show relationship of points A and B to the
vaginal fornices and uterus as described using the Manchester system.
1.2.2 International Commission on Radiation Units (ICRU) Report 38 Guidelines for ICBT
of Cervical Disease
The International Commission on Radiation Units (ICRU) Report 38 introduced a
dosimetry system, incorporating recommendations of the European Group of Brachytherapy,
which recommends specifying prescription dose to a target volume, rather than to a discrete
3

point [2]. The method addresses the inherent ambiguity of dose delivered to a target volume
when merely prescribing dose to a set of points. For an ICBT cervical treatment, the report
recommends dose to be prescribed as an isodose surface that surrounds the target volume (uterus,
cervix). Recommendations are given to use certain points for reporting dose to organs at risk
(OAR) such as the bladder point, rectal point, lymphatic trapezoid of Fletcher points, and pelvic
wall points. However, it has been shown that the ICRU reference points for the bladder and the
rectum do not necessarily indicate the maximum dose delivered to these OARs [3]. 3D treatment
planning analysis has shown maximum bladder doses and maximum rectal doses can be as much
as 2.3 and 1.3 times higher, respectively, when determined using computed tomography (CT)
relative to the ICRU reference points [4].
1.2.3 American Brachytherapy Society Guidelines for ICBT of Gynecological Disease
The American Brachytherapy Society recommends prescribing dose for cervical ICBT to
a new point, other than point A, where it is farther from the high-dose gradient fall off from the
ovoids [5]. This point, designated point H, relocates the prescription point away from the highdose high-gradient fall off region that the ICRU/Manchester point A lies within, to an area of
high-dose, low dose-gradient fall off. It was suggested as a minor change in the location of point
A because it results in a significant difference in dose which may lead to inconsistencies in
patient treatments. This new point (Point H) is located 2 cm superiorly to the cervical os plus the
radius of the ovoids, and then 2-cm in the lateral direction.

1.3 Dose Calculation Methods for Brachytherapy
Accurate dose calculation of an ICBT cervical treatment is an important and challenging
task. In general, radiation dose calculations involve the determination of the amount of energy
deposited within a volume or point of interest. Manual dose calculations utilize published tables
which characterize a dose distribution for a specified isotope and encapsulation in a
4

homogeneous material where the reference dose rate is estimated and the treatment time is
calculated. Although manual tables are convenient for two dimensional (2D) dose calculations,
treatment planning system (TPS) computers are able to quickly calculate dose to a three
dimensional (3D) volume. Also, because the human body is not homogeneous, it would be
advantageous for a calculation method to take into account tissue heterogeneities.
1.3.1 Analytical Method: American Association of Physicist in Medicine Task Group-43
(AAPM TG-43) Methodology
Most commercially available brachytherapy TPS utilize the dose calculation methods
presented within the American Association of Medical Physics Task Group-43 (AAPM TG-43)
report published in 1995 which characterizes the dose distribution in water as a function of
isotope and source construction. This report presented a formalism that clearly defines the
necessary physical quantities for point dosimetry [6]. The formalism has one dimensional and
2D formats: the point-source approximation and the line-source approximation. For dose
distributions resulting from multiple sources or single source plans with multiple dwell-positions,
this methodology relies on superposition of single-source dose distributions. This method
assumes a 3D cylindrically symmetrical dose distribution as the calculation utilizes a 2D dataset
for commissioning.
The AAPM TG-43 2D dose rate calculation equation is:

G (r ,  )
D (r , )  S k   
 g (r )  F (r ,  )
G(r0 , 0 )

(1.1)

where r denotes the distance from the center of the radioactive source to the point of interest, and
θ denotes the polar angle specifying the point-of-interest relative to the source longitudinal axis.
As illustrated in Figure 1.3, the reference angle, θ0, and reference distance, r0, define a point on
the source transverse plane, and are specified to be 90° and 1 cm, respectively.

5

Figure 1.3: Definition of the coordinate system utilized within the AAPM TG-43
formalism.
Air-kerma strength, SK, is the air-kerma rate, Kδ (d), in vacuo, due to photons with
energies greater than δ, at distance d from the source, multiplied by the square of this distance.
Air kerma rate measurements should be made in air and corrected for photon attenuation and
scattering in air between the source and detector. In lieu of measurements, Price et al. has shown
that a Monte Carlo (MC) simulation can be used to calculate air kerma rate [7]. The distance d
can be any distance that is large relative to the maximum linear dimension of the radioactivity
distribution so that SK is independent of distance [1]. The units of air-kerma strength, denoted as
U, are μGy h-1 m2.
The dose-rate constant, Λ, depends on both the radionuclide and source model, and is
influenced by the source encapsulation’s internal design. The definition of the dose-rate constant
in water is the ratio of dose rate at the reference position to SK :

D (r0 , 0 )

Sk

(1.2)

The radial dose function, g (r), accounts for dose fall-off on the transverse-plane due to
photon scattering and attenuation, and is defined as:

6

D (r , 0 )  G(r0 , 0 )
g (r ) 
D (r0 , 0 )  G(r , 0 )

(1.3)

At the reference point, the radial dose function is equal to unity.
The 2D anisotropy function, F(r, θ), describes the variation in dose due to self-absorption
of radiation as a function of polar angle relative to the transverse plane.

D (r , )  G (r , 0 )
F (r , ) 
D (r , 0 )  G (r , )

(1.4)

At the reference point, the anisotropy function is equal to unity.
Physically, the geometry function, G(r, θ), neglects scattering, attenuation, radionuclide
energy spectrum, and accounts for the inverse square dose fall off and distribution of radioactive
material inside the radioactive source on the dose distribution at a given point.



 L  r  sin  ,  0
G (r ,  )  
(r 2  L2 ) 1 ,   0
4


(1.5)

where L is the length of the radioactive source, and β is the angle subtended by the radioactive
source with respect to the point of interest.
1.3.2 Deterministic Method: Monte Carlo Technique
The transport of radiation through matter is a stochastic process and can be simulated
modeling physical law combined with the probabilities of interactions. For this type of
application, a MC simulation is based on a repeated random sampling of particle histories to
simulate random trajectories of individual particles. A single history finishes when the primary
particle and all its liberated secondary particles lose enough energy that the remainder is
considered negligible. Each history serves as an independent sample contributing towards the
simulation result or tally, which is a statistical estimate of an actual dose distribution. When
7

enough histories are simulated, the central limit theorem applies and accurate dosimetric
information on the transport process may be obtained by averaging over the entire simulation
tally. Also, Strong’s theory of large numbers says that results obtained from a large set of trials
should be close to the expected value, and will tend to become closer as more trials are
performed. Applications of MC techniques in medical physics, especially radiation therapy
physics, have been discussed in numerous publications [8-10]. MC is considered the “gold
standard” for dose computation accuracy once its application has been validated experimentally.
To accurately simulate a dose distribution using MC, the user must correctly model the
geometry of the problem. The MC input file contains information about the geometry and
material specification; the location and characteristics of the source; and any type of answers or
tallies applicable. MC is able to simulate photon interactions such as the photoelectric effect,
characteristic x-rays, coherent scattering, Compton scattering, and pair production [11].
Serial computation of millions of histories involves a significantly large amount of
computing time. The MC calculation time is affected by the solid-angle effect and inversesquare law fall off of the radiation from the radioactive source since they result in fewer
simulated photons at a distance away from the source. According to the central limit theorem,
the relative error is proportional to 1/√ , where N is the number of histories; and is used as a
surrogate for computational time. The serial MC method requires long calculation times to
generate dose distributions with satisfactory statistical uncertainties. To circumvent long
computation times, MC parallel processing is able to simulate and track particle histories
independently and simultaneously; the histories can be separated into several batches and
executed in parallel. As of 2010, the Monaco TPS version 2.03 is the only commercially
available MC-based treatment planning system for EBRT.

8

1.4 ICBT Applicators and Their Dosimetric Effect
Unfortunately, current clinical TPS are typically unable to accurately account for the
dosimetric effects of additional source encapsulation, such as polysulfone and high-Z shielding,
provided by the applicator in certain HDR ICBT techniques. These TPS systems utilize the TG43 algorithm which does not provide a method to quantify the attenuative effects when
calculating dose. The TG-43 formalism assumes calculations are in water. As such, errors of
5% - 30% or more may occur in planned dose to OARs [12-13]. Also, brachytherapy applicators
which produce a non-cylindrically symmetric dose distribution cannot be incorporated into the
TG-43 2D formalism.
One way to account for these dose perturbations is through the use of the MC technique.
But, due to the intense computational time requirements for MC dose calculations, clinical use of
MC for ICBT treatment planning is impractical. Investigations have been made into the use of
pre-calculated MC data sets which characterize common brachytherapy dose distributions which
are then applied to patient-specific geometries [14-15]. The technique presented by Rivard et al.
(i.e. the Tufts technique) treats the brachytherapy applicator as an additional source
encapsulation and employs MC to generate new TG-43 2D relative parameters (i.e. radial dose
function, anisotropy function) specific to the radioactive source and brachytherapy applicator
combination [15] which is then implemented into the TG-43 2D dose calculation. The TPS is
then able to generate a 3D dose distribution that incorporates the applicator’s attenuative effect
into superposition calculations using MC-generated dose distribution parameters. However, this
technique is only applicable to brachytherapy applicators that deliver a cylindrically symmetric
dose distribution as TG-43 methods are limited to 2D.
Price et al. developed a rudimentary TPS that utilized pre-calculated MC data sets to
simulate patient ICBT treatments delivered using a shielded tandem and ovoid applicator [16].
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Because the system determined total dose to the patient through the superposition of dose
distributions resulting from individual source dwells, a large number of MC simulations were
required for commissioning. The systems required, as input, a simulated distribution for each
possible source dwell-position, for each ovoid (left and right), for all possible ovoid lateral
separations. As such, robust commissioning of the system was time prohibitive when one
considers that for acceptable accuracy, a simulation of a few hundred million histories is required
for each possible source position. In spite of these shortcomings, when commissioned with
limited data applicable to a specific patient geometry, Price et al. reported a 94% agreement in
dose to a clinically-applicable volume for a simulated patient treatment when compared to an
equivalent volume whose ICBT delivered dose was simulated explicitly using MC techniques.
The benefit of Price et al.’s system was in that their results were obtained nearly 5000 times
faster than explicit MC system modeling and simulation. To reduce the commissioning
requirements and extend the practicality of Price’s system, the minimum amount of
commissioning data required to produce a clinically viable pre-calculated MC-based TPS for
ICBT must be determined.
In this work we present a modification to the method of Price et al. that, rather than
employing pre-calculated MC data sets directly for dose determination, implements MC-based
correction factors that correct for shortcomings intrinsic to TG-43 methods (more detailed
discussion on correction factors in Chapter 2). When applied to TG-43 calculated dose, these
correction factors will account for any dosimetric effects due to the presence of ICBT applicators
during treatment delivery. The motivation driving this modification is that it facilitates the
method’s integration into existing, commercially-available TPS. Additionally, it is thought that
by taking into account the dominant dosimetric effects of inverse-square falloff of dose with
distance from the source (via TG-43 methods) as well as the attenuative effects of the ICBT
10

applicator (via MC-correction factors), an accurate patient dose calculation can be made while
by-in-large ignoring the secondary influence of scatter due to tissue inhomogeneities. However,
verifying this expectation is beyond the scope of the presented work.

1.5 Hypothesis and Specific Aims
A 3D Monte Carlo-simulated dose distribution of the ovoid contribution to a cervical
intracavitary brachytherapy (ICBT) treatment administered via Nucletron’s Fletcher CT-MR
ovoid applicator (Nucletron Corporation, Veenendaal, The Netherlands), modeled with and
without a rectal shield surrogate, will agree, within criteria, with the dose distribution resulting
from an equivalent treatment calculated using AAPM Task Group-43 (TG-43) methodology
when corrected for heterogeneities using pre-calculated MC correction factors applied (a) to
individual source dwell-positions and (b) individual ovoids acting as multi-source surrogates for
varying adjacent dwell-time gradients (∇dt). Criteria are defined as agreement within +/- 2%
dose or +/- 2 mm distance-to-agreement (DTA).
Three aims have been completed to test this hypothesis:
1.5.1 Aim 1. Confirm a Monte Carlo Model of A Paired Nucletron Fletcher CT-MR Ovoid
Applicator.
A Monte Carlo (MC) model of the Nucletron high-dose rate (HDR) ICBT CT-MR
compatible Fletcher ovoid set will be created and experimentally confirmed via film dosimetry.
Absolute dose measurements will be made in two perpendicular planes, (a) 1 cm beyond the
distal end and (b) 3.3 cm from, and parallel to, the long axis of a single ovoid. Measurements
will be carried out in water.

1.5.2 Aim 2. Create a Library of 3D Correction-Attenuation Matrices.
Two MC models will be used to simulate 3D dose distributions in water for clinically
relevant microSelectron HDR (mHDR) Ir-192 dwell-positions. The two MC models will model
(1) the commercially-available CT-MR compatible Fletcher ovoid confirmed in Aim 1 and (2) a
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modified version of that includes a high-Z heterogeneity acting as a rectal shield surrogate.
These distributions will take into account source loading geometry as well as dose perturbations
due to the ovoids. From this data, a library of 3D attenuation-correction matrices will be
developed that characterize the dosimetric effect of the commercial ovoid as well as the modified
ovoid model to create both source- and ovoid-based correction factors.
1.5.3 Aim 3. Apply Attenuation-Correction Matrices To Treatment Planning SystemCalculated Dose Distributions And Compare To Monte Carlo Calculations.
The two sets of ovoid and source-based correction attenuation matrices will be applied to
3D dose distributions calculated by the Oncentra Brachytherapy treatment planning system,
which utilizes TG-43 dose-calculation methodology, in an attempt to reproduce MC-simulated
dose distributions of equivalent treatment geometries. The two sets of correction factors will be
applied to different plans varying the ∇dt of each ovoid. Agreement criteria will be applied and
the hypothesis will be tested.
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Chapter 2 Methods and Materials
2.1 Aim 1: Monte Carlo Confirmation Method
For Monte Carlo (MC) modeling of the Ir-192 high dose-rate source and ICBT applicator
ovoids, Monte Carlo N-Particle eXtended (MCNPX) transport code was employed. This MC
package is capable of simulating transport of a variety of particles in complex, three dimensional
geometries [11]. The validated MC model of the microSelectron v2 HDR (mHDR v2) Ir-192
source (Nucletron Corporation, Veenendaal, The Netherlands) presented by Price et al. is
utilized for all source simulations within this study and its design and material description can be
found in their work [7]. Price et al. showed that MC simulated dose for a medial plane with
effects from a high-Z shield was in agreement with radiochromic film measurements for 91% of
the comparison points within +/-2% or +/- 2mm and approximately 98% were within +/-10% or
+/-2mm distance-to-agreement (DTA) [17].
2.1.1 Nucletron CT-MR Compatible, ICBT Ovoid MC Modeling
Detailed physical measurements of Nucletron’s CT-MR compatible tandem and ovoid
applicator were performed in-house to facilitate construction of a MC model of the device. The
model consists of an ovoid set and does not include the intrauterine tandem. The tandem was
excluded due to its cylindrical symmetry and thin wall (≈ 1 mm) construction of nearly tissue
equivalent material. As such, dose calculated using TG-43 based or MC methods in a
heterogeneous volume differ within the uncertainty of the MC calculation method.
To ensure dosimetrically accurate simulations, it is important to model the entire physical
system with sufficient precision when utilizing MC methods. Therefore, the model used for this
study included a paired of left and right ovoids that can house the mHDR v2 Ir-192 source in a
variety of clinically applicable dwell-positions. For this work, dwell-positions were limited to
four (4) per ovoid with a separation of 5 mm between possible source positions. Although only
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one ovoid can be “active” (i.e. contain the stepped radioactive source) at any one time, all
simulations included its “inactive” pair as it has been shown that dose discrepancies up to 14%
may result when the inactive ovoid is not explicitly modeled [16]. This effect is especially true
for shielded applicators. The material, density, and composition of each component of the MC
model used within this study are shown in Table 2.1. A two-dimensional graphical
representation of the study’s MC model is shown in Figure 2.1 (a) through (c).
A few geometric features of the components were simplified to reduce the complexity of
the MC input file while maintaining dosimetric accuracy at relevant clinical distances from the
ovoid surface. These include: (1) omitting the long handle of each ovoid, (2) approximating the
retaining screw as a cylinder, (3) simplifying the shape of the intrauterine tandem flange spacer,
(4) approximating the curvature of the colpostat shaft as two intersecting cylinders, and (5)
modeling a length of 2 cm to approximate the braided steel cable attached to the proximal end of
the mHDR v2 Ir-192 source. It is also assumed for simulations that the mHDR v2 Ir-192 source,
when deployed from the after loader, lays exactly along the central shaft of the ovoid. As the
nominal inner diameter of the source lumen within the ovoid shaft is 3.5 mm, the modeled
source, which has a 0.9 mm outer diameter, could be off center by, at most, 1.3 mm [16].
Assuming inverse square is the predominate effect; the uncertainty of absolute dose, directly
adjacent to the ovoid, may be affected by the source being off center.
The superposition of simulated dose matrices of individual Ir-192 source dwell-positions
is required due to the density of the iridium source causing large anisotropy effects when sources
are simulated simultaneously. Multiple dwell-positions simulated simultaneously are not an
accurate representation of an actual loaded HDR ICBT treatment where a single source is
positioned at varying dwell points within the ovoid shaft at different times.
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Table 2.1: Materials of structures used in the CT-MR Fletcher ovoid set Monte Carlo
simulations, their compositions listed by weight and density. Dry air is defined at sea level (1
atm) and 20º C.
Composition
Structures
Material
Density (g cm-3)
(% by weight)
Source encapsulation, AISI 316L stainless
Mn 2.0
8.02
a
braided steel cable
steel, conductor
Si 1.0
4.81a
Cr 17.0
Ni 12.0
Fe 68.0
Film phantom
Liquid water
H 11.2
1.0
O 88.8
Ovoids
Polysulfone
C 66.0
1.29
O 22.0
S 7.4
H 4.6
Outside of water
Dry air gas = 1 b
C 0.0124
1.205 x 10 -3
phantom, interior of
N 75.5267
ovoid, interior of
O 23.1781
ovoid shaft, canal
Ar 1.2827
where retaining screw
is fitted
Radioactive source
Iridium-192
Ir 100
22.42
a
-3
Braided steel cable density is 4.81 g • cm
b
Gas state defined on material card in MCNPX
2.1.1.2 The 192Ir Energy Spectrum
The mHDR Ir-192 source has a half-life of 73.83 days and an average energy of 0.38
MeV. It decays by emitting beta particles and gamma radiation. It is produced by neutron
activation of iridium metal in a nuclear reactor. The energy spectrum utilized for 192Ir source
simulations is that reported by Glasgow and Dillman[18]. They reported that gamma and x-rays
of energies less than 11.3 keV cannot penetrate through the high-Z source encapsulation and
should not be included in the determination of the total specific gamma-ray constant, total
specific x-ray constant, and total exposure rate constant. The total number of photons emitted
per disintegration was determined to be 2.32 by Price et al. [7]. This factor was used to convert
the MC dose rate estimate per photon to the dose rate estimate per source contained activity in
Equation 2.1.
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(a)

(b)

(c)
Figure 2.1: Two-dimensional plots of the CT-MR Fletcher ovoid applicator set
using the MCNPX graphical plotter through a.) the ZX-plane bisecting the ovoid
shaft, b.) the ZY-plane bisecting the ovoid shafts in the left/ right ovoids and
c.) the XY-plane bisecting the ovoid shaft. Colors show different materials
where blue, yellow, and red are water, Polysulfone, and air, respectively.
2.1.1.3 The Tally Type, Mesh Size, and Relative Error of MC Dose Estimates
The MCNPX “mesh” tally (F6:photons) type was utilized for study simulations. The
tally size for this study was a 10 x 10 cm3 plane with 1 mm3 voxels. The type of tally utilized in
this study scores the average energy deposition per unit volume (MeV cm-3 particle-1). Tracked
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particle interactions were limited to photons as the energy deposition for non-tracked secondary
particles (i.e., electrons) was assumed to be constrained to within close proximity of the collision
site [11]. Since secondary particles from low energy photons have a relatively short path length,
compared to the voxel size, this tally yields a good approximation of collision kerma [16, 19-21].
The normalization is per unit cell volume, not per unit mass, since the mesh cell may cover
regions of different masses.
Due to the inverse-square law fall off of emitted radiation, voxels far from a simulated
source will record fewer histories compared to those more proximal. For each tally voxel, MC
reports an estimation of relative error, R, corresponding to one estimated standard deviation.
The relative error is proportional to 1/√ , where N is the number of particle histories.
Therefore, relatively large number of particle histories must be simulated in order to obtain
energy depositions of acceptable error. Since MC estimates of collision KERMA depend largely
on simulated interaction cross-section data, the accuracy of these libraries plays an important role
in the validity of simulated interactions. As such, all cross-section libraries utilized in this work
have been vetted by Los Alamos National Laboratory [11]. Finally, an additional source of error
may lie within the inaccuracies of modeled geometries. If errors exist in any of these study
components (modeled geometry, energy spectrum, and interaction cross-section) disagreements
will exist between simulated and measured dose distributions. Therefore, film measurements
have been performed to confirm the accuracy of the MC modeling of the ovoids.
2.1.1.4 Conversion of MC Calculated Quantities to Absolute Dose
MCNPX mesh tally simulations are recorded as units of energy deposition per unit
volume per simulated particle [MeV cm-3 particle-1]. To convert to absolute dose rate per
contained activity, a method presented by Price et al. (2005) is utilized:
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Defining terms that are not simple conversions, 2.324 particles disintegration-1 is
determined from the source spectrum utilized for MC simulations [18]. The conversion factor of
1.13 contained to apparent activity was determined by Price et al. 2005. A 1-Ci apparent activity
of an encapsulated radioisotope source is defined to be the amount of encapsulated source that
gives rise to the same exposure in air as an unencapsulated source of the same isotope of 1-Ci
(contained) activity. The definition of 0.243 mCi ≡ 1 μGy m2 h-1 defines the relationship of Sk to
apparent activity for Ir-192 [1, 19].
To calculate the absolute dose per dwell-position for an ICBT HDR administration,
Equation 2.2 was used:
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(2.2)

where t[min] is the active dwell-time. The conversion factor for air kerma strength to apparent
activity for an Iridium-192 source is 0.243 mCi U-1 [1].
2.1.2 Radiochromic Film Model Confirmations
For model confirmation, the mHDR v2 192Ir source was positioned at three dwellpositions within the colpostat and films were exposed in two perpendicular orientations.
Radiochromic film (RCF) was utilized for this work due to its high spatial resolution, minimal
energy dependence, insensitivity to ambient light, its ability to be immersed in water and near
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tissue equivalence [22]. RCF consists of a thin (7 - 23 µm), radiosensitive layer of monomer
crystals, dispersed in gelatin, bonded to a Mylar base [1]. When high-energy radiation interacts
with the active layer, the monomer is polymerized, increasing the saturation of the dye’s color in
proportion to the amount of radiation absorbed. Gafchromic dosimetry media type MD-55-2
(International Specialty Products Technologies, Wayne, NJ) radiochromic film (Lot #
R0419MDV2) was used for MC model confirmation of the CT-MR ovoid applicator set in a
liquid water phantom. Since dose distributions in water were required for this MC model
confirmation, the ability to submerge the film in water and to handle film in room light greatly
simplifies the setup process. According to the vendor, RCF is suitable for dose measurements
within the range of 3 to 100 Gy. The American Association of Physicists in Medicine (AAPM)
has published detailed characteristics of this type of film and their suggested film handling
recommendations were followed [22].
2.1.2.1 Film Calibration
A single calibration curve was used to calibrate films from the same manufacturing lot.
Calibration curves were determined using 13 measurements acquired using 2 x 2 cm2 pieces of
film cut from a single sheet. The same corner of each individual pieces of film were marked in
order to allow consistent, identical film orientation for film digitization [22]. Films were
calibrated by placing the film perpendicular to an en face 4 MV beam set to 100 cm source to
axis distance (SAD), placing 10 cm of Plastic Water on top of the film with 5 cm below for
sufficient backscatter. The pieces of film were then separately irradiated in the center of an open
10 x 10 cm field to: 3, 5, 10, 23, 25, 28, 30, 33, 35, and 38 Gy. One piece of film was not
irradiated and used to provide the background / fog color saturation (optical density) level of the
film.
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As recommended by AAPM Task Group-55, irradiated RCFs were stored for at least 48
hours prior to scanning to allow for film development under ambient conditions (temperature ≈
23o C, relative humidity ≈ 30o C) with nominal exposure to fluorescent room lights. Irradiated
films were digitized using an Epson Perfection V700 Photo flatbed scanner (Seiko Epson
Corporation, Nagano, Japan). The 16-bit red channel image was exported for film analysis as the
absorption peak of RCF film lies at ≈ 773 nm, which corresponds to the scanner’s red channel.
A scanning resolution of 96 dpi (≈ 0.3 mm pixel-1) was used for film digitization.
After digitization of the calibration films, Image J (Image J, Bethesda, Maryland)
software was utilized to measure the average scanner value for a 1 cm2 region in the center of
each film piece to correlate the scanner value to known dose values. Image J freeware is a public
domain image processing program that can be used for image analysis [23]. After plotting the
scanner values vs. absorbed dose, a second order polynomial was fit to the resulting curve to
convert film scanner values to absorbed dose as shown in Figure 2.2.

RCF calibration curve
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Scanner Value

45000
40000
35000
30000
25000
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0
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Figure 2.2: RCF measured calibration points used to convert RCF readings to
dose.
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2.1.2.2 Treatment Planning for Model Confirmation Film Irradiations
The Nucletron Corporation Oncentra brachytherapy treatment planning system
(Veenendaal, The Netherlands) was used to determine the dwell-time required to deliver a 10 Gy
to a point 1.7 cm away and perpendicular to the long-axis of a source positioned 5mm proximal
and distal to, two adjacent dwell-positions (three dwell-positions total) (c.f. Figure 2.3). An
additional plan was constructed that determined dwell-times for three sources in an equivalent
orientation that delivered 10 Gy to a point that lay 3.3 cm away and parallel to the long-axis of
the middle dwell-position (c.f. Figures 2.3). These points were selected to act as surrogates for
the rectal and disease plane, respectively. With air kerma strength of 32701 μGy m2 h-1, the
resulting treatment plan for both planes called for indexer lengths of 1500 mm, 1495 mm, and
1490 mm with a total dwell-time evenly distributed for all dwell-positions of 10.9 min and 18.3
min for the rectal plane and disease plane, respectively. A radiograph was inspected to confirm
source position / indexer length correspondence of the ovoid applicator set to the MC modeling
of the source position within the ovoid.
2.1.2.3 Phantom Film Measurement Setup
In-room patient setup lasers were used to align the colpostat shaft perpendicularly to the
rectum surrogate film plane (c.f. Figure 2.3a) or parallel to the disease surrogate film plane (c.f.
Figure 2.3b). Films were placed atop slabs of Solid Water submerged within the water phantom.
Room lasers were also used to carefully orient each film in a reproducible fashion. Once
properly aligned, the ovoid was attached to the mHDR afterloader (Nucletron, Veenendaal, The
Netherlands) and plans were delivered. Each plan was delivered three times to for a total of 6
measurements.
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Figure 2.3: Monte Carlo model film confirmation phantom. (a) The GafChromic
film is shown in the “rectum plane” orientation. (b) The GafChromic film is
shown in the “medial plane” orientation. The ovoid, water tank, and film were
aligned using vault lasers.
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2.1.2.4 Film Data Processing and Analysis
The average of three measurements was acquired for each plane measured for the MC
model confirmation. The standard deviation, σ, between three measurements was calculated to
compare pixel to pixel for each film.
MC confirmation RCF measurements were processed following the same methods
utilized for RCF calibration. All films were scanned in equivalent orientations and locations on
the flatbed scanning window. In-house software was developed using Matlab v7.8 (2007a, The
MathWorks, Natick, MA) for all data processing. The software was written to facilitate
importation and processing of the digitized TIFF images as well as the conversion of raw image
data (scanner values) to absorbed dose [Gy]. To reduce inherent image noise, an adaptive 2-D
Wiener filter was applied to all scanned film data. To perform an analysis, the algorithm first
down-sampled the red channel of the TIFF image so as to spatially match the MC dose array and
then registered the RCF film data to the MC simulated dose. Software written in Matlab allowed
incremental 1 mm shifts to the film data in the up, down, left, and right directions in order to
spatially match the MC simulated dose. Table 2.2 lists the uncertainty components associated
with MC model confirmation film measurements. An expanded uncertainty of 11% is the total
uncertainty in measurements.
Film measured dose distributions were compared to MC simulations to evaluate the
dosimetric accuracy of the MC model. The comparison consisted of determining the number of
points within an arbitrary percent agreement as well as distance-to-agreement (DTA). The
algorithm selected a corresponding point from both data sets and determined whether or not the
percent difference passed the dose criteria (e.g. 2%) using:

% Difference 

Film (i, j )  MC (i, j )
MC (i, j )
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100%,

(2.3)

where i and j are indexes used to define pixel location (row and column). If this point is within
the dose criterion, the algorithm continues to the next point in the data set. If the point is not
within criteria, the algorithm searches for a point within the distance criteria (e.g. 2 mm) for a
value that meets the dose criteria. This is repeated for all corresponding points in the MC and
image data set. An overview of this process is shown in Figure 2.4.
Table 2.2: Estimated relative uncertainties of the radiochromic film dose interpretations per
measured unit reference air kerma rate.
Uncertainty component
Calibration of the 4MV LINAC
Response of the film exposed to the LINAC
Response of the films exposed to the source
under test
Sk calibration for source under test
Combined standard uncertainty
Expanded uncertainty (k=2)
a
Nucletron Certificate for Sealed Sources.

Relative one standard uncertainty (%)
3.0
3.0
3.0
1.67 a
5.5
11

Figure 2.4: Illustration of comparison algorithm. *Values below 3 Gy (as
recommended by TG-55) are not included in the comparison. **If one point
passes the tolerance and distance condition, then point (x, y) passes.

2.2 Aim 2: Development of 3D Attenuation Correction Factor Database
Two MC models will be used to simulate 3D dose distributions in water for clinically
relevant mHDR Ir-192 dwell-positions. The two MC models will model (1) the commerciallyavailable CT-MR compatible Fletcher ovoid confirmed in Aim 1 and (2) a modified version of
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that includes a high-Z heterogeneity acting as a rectal shield surrogate. A two-dimensional
graphical representation of the study’s modified MC model is shown in Figure 2.5. Because the
CT/MR compatible Fletcher ovoids are not available in a shielded model, this modification was
included in this study as a proof of principle for this correction scheme. Clinical shielded ovoid
applicators contain 1.7 mm tungsten “half discs” compared to the rounded distal end being
comprised of metal. Dose perturbations are expected to be significant with the modified shield
as opposed with an actual clinically available shield.

(a)

(b)

Figure 2.5: Two-dimensional plots of the modified CT-MR Fletcher ovoid
applicator set using the MCNPX graphical plotter through a.) the ZX-plane
bisecting the ovoid shaft, and b.) the ZY-plane bisecting the ovoid shafts in the
left/ right ovoids. Colors show different materials where blue, yellow, green, and
red are water, polysulfone, tungsten, and air, respectively.
To create the MC attenuation-correction dataset libraries, a mesh tally (F6: photons), 10 x
10 x 10 cm3 in size was used to tally energy deposition per particle within 1 mm3 voxels. A total
of eight source-dwell indexes: 1500 mm, 1495 mm, 1490 mm, and 1485 mm (measured from the
afterloader port) for both right and left ovoids, were simulated. The origin of each mesh tally
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was positioned to coincide with the geometric center of the mHDR v2 Ir-192 source. All
simulations were run for 260 x 106 histories to achieve a statistical uncertainty of less than 2% at
the most distant elements of the tally grid. Due to the computing time required for simulations of
this magnitude, a parallel-processing capable, super-computing cluster was used for these
simulations. The Tezpur super-computing cluster (Louisiana State University High Performance
Computing Department) is a 360 node cluster able to perform 15.3 x 1012 floating point
operations per second. Since MC simulates and tracks every particle history independently, the
histories can be grouped into several batches and executed in parallel. A single 260 million
history simulation (101 x 101 x 101, 1 mm3 tally voxels) ran parallel on 100 processors required
approximately 10 hours. To test the hypothesis, the following two methods were employed to
calculate the attenuation-correction matrices.
2.2.1 Method 1: Ovoid-Based Correction Factor, cO
The ovoid-based correction factors, cO, were calculated using:

d OMC ( x, y, z )
cO  TG 43
,
d O ( x, y , z )
where

(2.4)

is dose rate per activity [Gy mCi-1 hr-1] to a voxel centered at (x, y, z) in the

experimental coordinate system converted from MC-calculated energy deposition per particle
using equation 2.1 and

is the dose rate per activity [Gy mCi-1 hr-1] to a voxel of

an equivalent position, in the same coordinate system, as calculated by the TPS using AAPM
Task Group 43 methodology [6]. The index, O, is equal to either 1 or 2, indicating the
handedness of the ovoid, patient right or left, respectively. Both

and

consist of the

superposition individual dose distributions of multiple dwells in each colpostat and the origin of
these matrices is defined to coincide with the most distal source-dwell-position (active) within
the corresponding ovoid:
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d

MC
O 1

( x, y, z )   d SMC ( x' , y ' , z ' )
S 1

and

(2.5)

8

d
where

MC
O2

( x, y, z )   d SMC ( x' , y ' , z ' )
S 5

is dose rate per activity to a voxel centered at (x’,y’,z’) in the Monte Carlo

coordinate system converted from MC-calculated energy deposition per particle using equation
2.1 for a single dwell-position. The index, s, corresponds to the dwell-position of the source
within the ovoid (i.e. s = 1 (1500 mm), s = 2 (1495 mm), etc.). Dwells 1 < s < 4 and 5 < s < 8 are
contained within the patient right and left ovoids, respectively. Provisions are made for clinical
applications that utilize both three (dwell-positions: s = 2 (1495 mm), s = 3 (1490 mm), and s = 4
(1485 mm)) and four (dwell-positions: s = 1 (1500 mm), s =2 (1495 mm), s = 3 (1490 mm), and
s = 4 (1485 mm)) inter-colpostatic dwells as both are common practice (i.e. 3 vs. 4 distributions
superimposed when calculating

).

, is the superposition of four dose

distributions for a single ovoid. This superposition is performed within the Oncentra TPS and
the origin of this distribution is defined to be in the geometrical center of the right or left ovoid
as a function of O within the experimental coordinate system. For the calculation of both
and

, source dwells were assumed to be coplanar, centered within the ovoid shaft, with the

geometric center of each source located at is corresponding dwell-position index (e.g. 1500 mm).
2.2.2 Method 2: Source-Based Correction Factor, cS
The source-based correction factors, cS, were calculated using (Equation)

d SMC ( x, y, z )
cS  TG 43
,
d S ( x, y , z )
where

(2.6)

is dose rate per activity [Gy mCi-1 hr-1] to a voxel centered at (x, y, z) in the

experimental coordinate system converted from MC-calculated energy deposition per particle
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using equation 2.1 for a single dwell-position and

is the dose rate per activity [Gy

mCi-1 hr-1] to a voxel of an equivalent position, in the same coordinate system, as calculated by
the TPS using AAPM Task Group 43 methodology for a single dwell-position [6]. The index, s,
is equal to values of 1 to 8, indicating the source position within of the ovoid (dwells 1 < s < 4
and 5 < s < 8 are contained within the patient right and left ovoids, respectively). Each
distribution’s origin is defined to coincide with the origin of the corresponding

dose

.

2.2.3 Analysis Software Development
In-house software was developed using Matlab v7.8 (2007a, The MathWorks, Natick,
MA) for all data processing. The software was written to facilitate importation, processing, and
analyzing the dose data sets generated by the TPS, MC, and correction procedure (utilizing
equations 2.3-2.6). The data sets were analyzed using a 3D distance-to-agreement algorithm,
which is illustrated in Figure 2.5. The algorithm selects a corresponding point from two data sets
and determines whether the percent error passes within the dose criteria (i.e. 2% tolerance). If
this point is within the dose criterion, the algorithm continues to the next point in the data set. If
the point is not within criteria, the algorithm searches for a point within the distance criterion
(i.e. 2 mm) for a value which passes within the dose criteria (i.e. 2% tolerance). This is repeated
for all points in the two data sets.

2.3 Aim 3: Application of 3D Correction Strategy to Patient Cases
2.3.1 DICOM
Digital Imaging and Communications in Medicine (DICOM) network protocol is a
standard that is a framework for handling, storing, printing, and transmitting medical-imaging
data [1]. The standard was developed in 1983 by the American College of Radiology (ACR) and
the National Electrical Manufacturers Association (NEMA) with input from various vendors,
academia, and industry groups. DICOM was developed as response to the need of a standard
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method for transferring images and related information between devices from different
companies. DICOM provides standardized formats for images, a common information model,
application service definitions, and protocols for communication. DICOM is useful in storing
and organizing radiotherapy plans because it groups information into data sets. For example, a
DICOM file stores image data (i.e. CT image) and patient information (i.e. name, patient
number, image type) within one file, so that the image can never be separated from the

Figure 2.6: Illustration of 3D dose tolerance and distance-to-agreement
algorithm. A point must pass the dose tolerance criteria or have another point
within the distance criteria which is within the dose tolerance, in order for (x, y)
to pass.
information by mistake. Oncentra uses the DICOM 3.0 standard for storage of the image data.
Oncentra exports three DICOM compliant files: (1) the DICOM Radiotherapy Plan (RP) file, (2)
the DICOM Radiotherapy Dose (RD) file, and (3) the DICOM Radiotherapy Structures (RS).
2.3.2 Application of Correction Factors to TPS-Calculated Plans
2.3.2.1 Attenuation-Correction Factor Calculation for Method 1
The TPS corrected dose [Gy] to a point located at (X, Y, Z) in the patient coordinate
system was calculated using:
2

TPS
cO

D

( X , Y , Z )   dOTPS ( X , Y , Z )  cO ( x, y, z ),
O 1
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(2.7)

where d OTPS is the superimposed ovoid-source surrogate dose distribution of either the left or right
ovoid (O=1 represents left ovoid and O=2 represents right ovoid) generated using Oncentra TPS.
The coordinate system of the ovoid-correction matrix, cO, was translated using MATLAB to
register and coincide with the TPS coordinate system (i.e. X, Y, Z) before it was applied. Two
correction matrices were applied to correct the exported TPS plan.
2.3.2.2 Attenuation-Correction Factor Calculation for Method 2
The TPS corrected dose [Gy] to a point located at (X, Y, Z) in the patient coordinate system was
calculated using:
8

TPS
cS

D

( X , Y , Z )   d STPS ( X , Y , Z )  cS ( x, y, z ),

(2.8)

S 1

where d STPS is the source dose distribution of dwell index S (S=1-4 represents indexes within left
ovoid and S=5-8 represents indexes within right ovoid) generated using Oncentra TPS. The
coordinate system of the source-correction matrix, cS, was translated using MATLAB to register
and coincide with the TPS coordinate system (i.e. X, Y, Z) before it was applied. Eight
correction matrices were applied to correct the exported TPS plan.
2.3.3 Case Selection
Three-dimensional planning for brachytherapy treatments requires modeling the patient
anatomy utilizing a set of 2D images that represent a patient’s anatomy in 3D, localizing the
dwell-positions in 3D, calculating appropriate dwell-times, and finally simulating the dose
distribution for the specified geometry. Treatment planning refers to the quantitative parts of the
process by which the individualized patient treatment plan is determined.
Dwell-positions in a co-planar geometry were exported using Oncentra TPS, and several
dwell-time combinations were investigated to test the hypothesis. This geometry was chosen
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because (1) the same geometry for dwell-position coordinates could be specified in the MC
coordinate system and (2) the voxel size was set to be equivalent to the MC models.
2.3.3.1 Maximum Adjacent Dwell-Time Gradient
Dwell-positions can be described according to their dwell-time as a relative difference known as
the dwell-time weighting factor, wn. The wn was calculated by using:

wn 

tn
,
Ttotal

(2.9)

where tn is the dwell-time at index “n” and Ttotal is the total dwell-time. The wn ranges from zero
to one (i.e. [0, 1]). A value of zero means that the dwell-time for that dwell-position is zero.
The adjacent dwell-time gradient, ∇dt, was calculated for every dwell-position by using:

 dt  wn wn 1 n 1
8

(2.10)

This equation determines the difference between adjacent wn. Calculations with a wn of zero are
ignored if that dwell index represents the distal or proximal end of the catheter.
Each comparison case was described by its maximum ∇dt. Several ∇dt (i.e. 0, 0.3, 0.6,
0.7) were used to analyze the effectiveness of both attenuation-correction factor methods. For
every case, a comparison of the TG-43 calculation to the MC simulation was made utilizing the
3D DTA algorithm for both ovoid- and source- based attenuation correction factors.
2.3.4 Analysis
Several dwell-time weighting differences were used to test the hypothesis. Each plan was
compared to its corresponding superimposed MC dose distribution to quantify the differences
due to the presence of the applicator ovoids. Also, the dose distribution resulting from both MC
models were compared to both corrected TPS plans (ovoid-based and source-based).
Comparisons were made by determining the percentage of points which agree within 2% or 2mm
DTA.
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Chapter 3 Results and Discussion
3.1 Aim 1: MC Modeling of a Nucletron ICBT CT-MR Fletcher Ovoid Applicator
3.1.1 Model Confirmation via Radiochromic Film
A comparison of radiochromic film (RCF) measurements and Monte Carlo (MC)
simulated absolute dose in water for two perpendicular planes in water are shown in Figures 3.1
– 3.2. Three independent RCF measurements were averaged, for both the “rectum” surrogate
and “disease” surrogate planes, and then spatially registered to the corresponding MC data set for
comparison. To register these data sets, software written in Matlab which shifted the dataset by
1 mm in the up, down, left, and right direction. Since the water phantom setup did not allow for
the RCF to be marked with respect to ovoid placement, registration was done visually in order to
best match up the isodose lines. Regions containing dose values less than 3Gy were not included
in RCF/MC comparisons per AAPM Task Group Report 55.
Qualitatively, one observes fair agreement of equivalent isodoses for compared data.
Quantitatively, MCNPX tallied dose agreed to within +/- 2% or +/- 2mm for 96% of the points
on the film acting as the “disease” surrogate and to within +/- 2% or +/- 2mm for 96% of the
points on the film acting as the “rectum” surrogate. The average standard deviation of the three
“disease” surrogate and “rectum” surrogate RCF measurement datasets are 11+/- 7.4 cGy and 9
+/- 7.0 cGy, respectively. The “rectum” surrogate film had regional discrepancies at the highdose gradient region near the center. This is possibly the result of the inverse square factor
having a strong influence in regions close to the source. The center point of the film was the
closest distance between the film plane and source. For MC, points farther from the center point
of the mesh (i.e. simulated film) plane result in a larger distance to the source reduces statistical
uncertainty. The “disease” surrogate film was 3.3 cm away from the source, in contrast to the
1.7 cm distance for the “rectum” plane, which results in less inverse-square influence. These
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results indicate that the models of the mHDR v2 Ir-192 source and paired ovoid component of
Nucletron’s CT-MR compatible applicator MC model are robust enough to simulate dose
distributions with sufficient accuracy within the context of this study.

Figure 3.1: Anterior rectal wall MC/RCF isodose contour comparison. Comparison of
MC (dashed) simulated and RCF (solid) measured dose, in cGy, for a plane located 1.7
cm distal to the distal surface of a single ovoid. This plane serves as a surrogate to the
anterior rectal wall of a patient. The simulation and measurements are for three (3)
dwell-positions indexed 1500, 1495, and 1490 mm from the afterloader exit port for
dwell-times of 1.2 minutes per source for an activity of 8.32 Ci. Quantitatively, 96% of
the comparison points are within +/- 2% or +/- 2mm.
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Figure 3.2: Lateral disease wall MC/RCF isodose contour comparison. Comparison of MC
(dashed) simulated and RCF (solid) measured dose, in cGy, for a plane located 3.3 cm
lateral to the long-axis of a single ovoid. This plane serves as a surrogate to the disease
wall, lateral to the cervix, of a patient. The simulation and measurements are for three (3)
dwell-positions indexed 1500, 1495, and 1490 mm from the afterloader exit port for dwelltimes of 6.1 minutes per dwell for an activity of 8.32 Ci. Quantitatively, 96% of the
comparison points are within +/- 2% or +/- 2mm.
3.2 Aim 2: Development of Ovoid and Source-Based Correction Factors
3.2.1 Nucletron MicroSelectron High-Dose Rate Ir-192 Source
Comparisons of MC-simulated isodose distribution and isodoses calculated using TG-43
methodology for a single mHDR v2 Ir-192 source in water with a source activity of 10 Ci and
dwell-time of 100 seconds is shown in Figure 3.3. Observed in this figure are the qualitative
differences in dose due to the different calculation methods and overlay of an Ir-192 source (not
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to scale). Quantitatively, 99.6% of the comparison points are within +/- 2% or +/- 2mm between
MC and TG-43 for a single source in water. The slight differences can be contributed to the
high-dose, high-dose gradient region near the source. In the lateral direction (i.e. parallel to y
axis), the isodose lines agree very well. The dose distribution along the longitudinal axis (i.e.
parallel to z axis) of the Ir-192 source is intrinsically anisotropic due to self-attenuation
throughout the high-density cylindrical Ir-192 core, asymmetric steel jacket construction, and
steel cable attached to one end of the source. With respect to the orientation of the mHDR v2 Ir192 source along its longitudinal axis, the forward direction for this comparison is –z direction
and the backward direction (along the braided steel cable) is +z direction. The MC simulation
predicts equivalent dose when compared to the dose distribution calculated using TG-43
calculations in the forward direction. Dose differences in the backward direction (i.e. with
respect to the longitudinal axis) can be a result of (1) the mathematical modeling error associated
with TG-43 methodology, (2) the MC photon transport code overestimating the anisotropy
factor, or (3) attenuation due to the 5 mm braided steel cable attached to the source. Reviewing
TG-43 source anisotropy factors utilized in the TPS, as expected, the dose distribution in the
backward direction is relatively less than in the forward direction. Thus, AAPM TG-43
methodology accounts for an asymmetric anisotropy factor due to the asymmetric source
construction.
3.2.2 Nucletron CT-MR Compatible Applicator
Comparisons of MC-simulated isodose distribution and isodoses calculated using TG-43
methodology for a single mHDR v2 Ir-192 source at multiple dwell indexes (e.g. dwell indexes
1500 mm, 1495 mm, 1490 mm, and 1485 mm) within a Nucletron CT-MR compatible applicator
in water (source activity of 8 Ci and dwell-time of 200 seconds) are shown in Figures 3.4

35

through 3.5. Shown in Figure 3.6 illustrates the superimposed dose distributions which are used
to create the ovoid- based correction matrix. Observed in these figures are the qualitative

Figure 3.3: Comparison of MC (red dashed) and TG-43 (solid blue) dose distribution,
in Gy, resulting from a single source in water with equivalent source activities and
dwell-time. Quantitatively, 99.6% of the comparison points are within +/- 2% or
+/- 2mm. The source is drawn to show perspective and is not drawn to scale.
differences in dose due to the perturbing effects of the ovoid accounted for in MC simulations
(dashed red lines) and unaccounted for in TG-43 calculations (solid blue line) for a single 2D
plane at each dwell index.

Differences along the longitudinal axis of the source can be

contributed to the air that is present within the ovoid shaft.

Quantitatively, >99% of the

comparison points are within +/- 2% or +/- 2mm for all comparisons. There are no appreciable
differences between the MC simulations of each dwell index with an TG-43 calculation. The
dose distribution is not significantly affected due to the presence of the CT-MR compatible
applicator.
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(a)

(b)

Figure 3.4(a-b): Comparison MC and TG-43 dose distribution for dwell index (a) 1500 mm and (b) 1495 mm, in Gy, within a plane
bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times. The source (blue cylinder,
not to scale) is illustrated within the ovoid to give perspective of placement. These plots illustrate
and
which are used to
create the source-based correction matrix. Quantitatively, > 99% of the comparison points are within +/- 2% or +/- 2mm for both
contour plots.
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(a)
(b)
Figure 3.5(a-b): Comparison MC and TG-43 dose distribution for dwell index (a) 1490 mm and (b) 1485 mm, in Gy, within a
plane bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times. The source (blue
cylinder, not to scale) is illustrated within the ovoid to give perspective of placement. These plots illustrate
and
which
are used to create the source-based correction matrix. Quantitatively, > 99% of the comparison points are within +/- 2% or +/2mm for both contour plots.
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Figure 3.6: Comparison MC and TG-43 dose distribution for superimposed dwell
indexes: 1500 mm, 1495 mm, 1490 mm, and 1485 mm, in Gy, within a plane bisecting
the right ovoid, resulting from four source dwell-positions with equivalent source
activities and dwell-times. The source (blue cylinders, not to scale) dwell-positions are
illustrated within the ovoid to give perspective of placements. These plots illustrate
and
which are used to create the ovoid-based correction matrix.
Quantitatively, 99% of the comparison points are within +/- 2% or +/- 2mm.
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3.2.3 MC Applicator Modified to Include High-Z Inhomogeneities
Differences between dose distributions resulting from the CT-MR compatible Fletcher
ovoid applicator in water and TG-43 calculation for a single source in water agreed within the
uncertainty of the MC simulation, a modification to include inhomogeneities within the MC
model was introduced. This high-Z modification was included in this study to test the robustness
of the correction scheme. Comparisons of MC-simulated isodose distribution and isodoses
calculated using TG-43 methodology for a single mHDR v2 Ir-192 source at multiple dwell
indexes (e.g. dwell indexes 1500 mm, 1495 mm, 1490 mm, and 1485 mm) within the MC model
modified to include a high-Z inhomogeneities (source activity of 10 Ci and dwell-time of 300
seconds) are shown in Figures 3.7 through 3.8. These figures show the isodose distribution
varies depending on which dwell-position is active. Figure 3.9 is the superimposed dose
distributions (i.e. all active dwell-positions) which are used to create the ovoid- based correction
matrix. Observed in these figures are the qualitative differences in dose due to the perturbing
effects of the tungsten shield introduced in the MC simulations (dashed red lines) and
unaccounted for in TG-43 calculations (solid blue line) for a single 2D plane.
Quantitatively, < 17.1%, 39.9%, 81.8%, and 89.0% of the comparison points are within
+/- 2% or +/- 2mm for dwell index 1500 mm, 1495 mm, 1490 mm, and 1485 mm, respectively.
The superimposed dose distribution had an agreement of 21.8% of the comparison points
agreeing within +/- 2% or +/- 2mm. The dose distribution is significantly affected due to the
presence of the tungsten shield. Dose distributions resulting from dwell-positions near the
tungsten shield (i.e. dwell indexes: 1500 mm, 1495 mm) are affected the most out of the four
dwell-positions. This is due to the Ir-192 source being contained within the high-Z metal.
Primary photons, thus scatter radiation, in the path of tungsten are significantly reduced because
of the high-Z attenuation.
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(a)

(b)

Figure 3.7(a-b): Comparison MC and TG-43 dose distribution for dwell index (a) 1500 mm and (b) 1495 mm, in Gy, within a
plane bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times. The source (blue
cylinder, not to scale) is illustrated within the ovoid to give perspective of placement. The distal end (green) of the ovoid was
modified to be tungsten with a density of 18 g/cm3. These plots illustrate
and
which are used to create the sourcebased correction matrix. Quantitatively, 17.1% and 39.9% of the comparison points are within +/- 2% or +/- 2mm for dwell
index 1500 mm and 1495 mm, respectively.
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(a)
(b)
Figure 3.8(a-b): Comparison MC and TG-43 dose distribution for dwell index (a) 1490 mm and (b) 1485 mm, in Gy, within a
plane bisecting the right ovoid, resulting from a single source with equivalent source activities and dwell-times. The source
(blue cylinder, not to scale) is illustrated within the ovoid to give perspective of placement. The distal end (green) of the ovoid
was modified to be tungsten with a density of 18 g/cm3. These plots illustrate
and
which are used to create the
source-based correction matrix. Quantitatively, 81.8% and 89.0% of the comparison points are within +/- 2% or +/- 2mm for
dwell index 1490 mm and 1485 mm, respectively.
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Figure 3.9: Comparison MC and TG-43 dose distribution for superimposed dwell
indexes: 1500 mm, 1495 mm, 1490 mm, and 1485 mm, in Gy, within a plane
bisecting the right ovoid, resulting from four source dwell-positions with equivalent
source activities and dwell-times. The source (blue cylinders, not to scale) is
illustrated within the ovoid to give perspective of placements. The distal end (green)
of the ovoid was modified to be tungsten with a density of 18 g/cm3. These plots
illustrate
and
which are used to create the ovoid-based correction matrix.
Quantitatively, 21.8 % of the comparison points are within +/- 2% or +/- 2mm.
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3.3 Aim 3: Application of Source- and Ovoid-Based 3D Correction Strategies
3.3.1 Nucletron CT-MR compatible Fletcher Ovoid Applicator
Two coplanar ovoids were simulated with all four (4) dwell-positions per ovoid lying in
the same plane. Points lying within the ovoid, for both MC simulations and TG-43calculations,
are not considered in comparison metrics as the dosimetry within the ovoids are of no clinical
significance. Dwell-time combinations were varied to test whether different dwell-time
gradients affect the efficiency of either correction scheme. Each plan was referenced according
to the maximum dwell-time gradient (i.e. 0%, 5%, 10%, etc.) in the combination of dwell-times.
A clinically applicable source activity of 8.7 Ci was used for all simulations.
3.3.1.1 No Dwell-Time Gradient
All dwell-times were equivalent and were set to 50 seconds. Comparisons of MCsimulated isodose distributions and isodoses calculated using TG-43 methodology is shown in
Figure 3.10. The CT-MR compatible Fletcher ovoid illustration is to convey the size and
placement of the ovoid pair. Although the plane bisects the source dwell-positions, the source is
not illustrated. Observed in this figure are the qualitative differences in dose due to the
perturbing effects of the ovoids accounted for in MC simulations (dashed red lines) and
unaccounted for in TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively,
99.8% of the comparison points are within +/- 2% or +/- 2mm. The differences between the two
isodoses are within the uncertainty of the MC.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.11a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan.
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Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.11b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. Again, there are
no appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.10: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a
source in water (blue). Maximum adjacent dwell-time gradient is zero. Both ovoids
are illustrated to show the plane and size of the ovoids. Shown here are absolute dose
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of
1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 99.8% of the comparison
points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.11(a-b): Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid
applicator vs. TG-43 corrected plans that account for applicator heterogeneities. Maximum adjacent dwell-time gradient is zero.
Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoidbased and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices:
1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm for
both comparisons.
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3.3.1.2 Dwell-Time Gradient of 30%
The dwell-times, keeping the same plan as previous, were manually set to 5 seconds for
dwell index 1500mm, 7.5 seconds for dwell index 1495mm, 45 seconds for dwell index
1490mm, and 67.5 seconds for dwell index 1485mm for both ovoids. The maximum dwell-time
gradient for this combination of dwell-times is 30%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.12. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 99.7% of the
comparison points are within +/- 2% or +/- 2mm. The differences between the two isodoses are
within the uncertainty of the MC.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.13a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 99.9% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.13b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
47

Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. Again, there are
no appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.12: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a
source in water (blue). Maximum adjacent dwell-time gradient is 30%. Both ovoids
are illustrated to show the plane and size of the ovoids. Shown here are absolute dose
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of
1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 99.7% of the comparison
points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.13: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid
applicator vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time gradient is 30%. Shown here are 2D
planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-based and (b) sourcebased corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 1500, 1495, 1490, 1485
mm for each ovoid). Quantitatively, 99.9% and 100% of the comparison points are within +/- 2% or +/- 2mm for the ovoid-based
and source-based corrected TG-43 plan, respectively.
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3.3.1.3 Dwell-Time Gradient of 60%
The dwell-times, keeping the same plan as previous, were changed to 5 seconds for dwell
index 1500mm, 5 seconds for dwell index 1495mm, 35 seconds for dwell index 1490mm, and
155 seconds for dwell index 1485mm for the left ovoid. The right ovoid dwell-times were
changed to 155 seconds for dwell index 1500mm, 35 seconds for dwell index 1495mm, 5
seconds for dwell index 1490mm, and 5 seconds for dwell index 1485mm. The maximum
dwell-time gradient for this combination is 60%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.14. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 99.0% of the
comparison points are within +/- 2% or +/- 2mm. The differences between the two isodoses are
within the uncertainty of the MC.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.15a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 99.7% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
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Figures 3.15b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. Again, there are
no appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.14: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a
source in water (blue). Maximum adjacent dwell-time gradient is 60%. Both ovoids
are illustrated to show the plane and size of the ovoids. Shown here are absolute dose
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of
1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 99.0% of the comparison
points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.15(a-b): Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid
applicator vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time gradient is 60%. Shown here are 2D
planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-based and (b) sourcebased corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 1500, 1495, 1490, 1485 mm
for each ovoid). Quantitatively, 99.7% and 100% of the comparison points are within +/- 2% or +/- 2mm for the ovoid-based and
source-based corrected TG-43 plan, respectively.
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3.3.1.4 Dwell-Time Gradient of 70%
The dwell-times, keeping the same plan, were changed to 25 seconds for dwell index
1500mm, 35 seconds for dwell index 1495mm, 2 seconds for dwell index 1490mm, and 150
seconds for dwell index 1485mm for the left ovoid. All dwell-times in the right ovoid were set
to 25 seconds. The maximum dwell-time weighting difference for this set is thus 70%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.16. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 99.6% of the
comparison points are within +/- 2% or +/- 2mm. The differences between the two isodoses are
within the uncertainty of the MC.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.17a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 99.9% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.17b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. Again, there are
no appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.16: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a CT-MR compatible Fletcher ovoid applicator (red) vs. TG-43 calculations for a
source in water (blue). Maximum adjacent dwell-time gradient is 70%. Both ovoids
are illustrated to show the plane and size of the ovoids. Shown here are absolute dose
comparisons, in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices of
1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 99.6% of the comparison
points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.17: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT-MR compatible Fletcher ovoid
applicator vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time gradient is 70%. Shown here are 2D
planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a) ovoid-based and (b) sourcebased corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices: 1500, 1495, 1490, 1485
mm for each ovoid). Quantitatively, 99.9% and 100% of the comparison points are within +/- 2% or +/- 2mm for the ovoid-based
and source-based corrected TG-43 plan, respectively.
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3.3.2 MC Applicator Modified to Include High-Z Inhomogeneities
The distal end of the ovoid material was converted to tungsten. Points lying within the ovoids,
for both MC simulations and AAPM TG-43calculations, are not considered in comparison
metrics as the dosimetry within the ovoids are of no clinical significance. Dwell-time
combinations were varied so that different maximum dwell-time gradients were compared to test
the hypothesis. A clinically applicable source activity of 8.7 Ci was used for all comparisons.
3.3.1.1 No Dwell-Time Gradient
All dwell-times were equivalent and set to 50 seconds. Comparisons of MC-simulated
isodose distributions and isodoses calculated using TG-43 methodology is shown in Figure 3.18.
The CT-MR compatible Fletcher ovoid illustration is to convey the size and placement of the
ovoid pair. Although the plane bisects the source dwell-positions, the source is not illustrated.
Observed in this figure are the qualitative differences in dose due to the perturbing effects of the
ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in TG-43
calculations (solid blue line) for a single 2D plane. Quantitatively, 13.2% of the comparison
points are within +/- 2% or +/- 2mm.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.19a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.11b. This figure illustrates the qualitative differences in dose for MC simulations
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(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. Again, there are
no appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.18: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a
modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield (red)
vs. TG-43 calculations for a source in water (blue). Maximum adjacent dwell-time
gradient is zero. Both ovoids are illustrated to show the plane and size of the ovoids.
Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four per ovoid,
dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively,
13.2% of the comparison points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.19(a-b): Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible
Fletcher ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time
gradient is zero. Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated
using (a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwellposition indices: 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 100% of the comparison points are within +/- 2%
or +/- 2mm for both comparisons.
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3.3.1.2 Dwell-Time Gradient of 5%
The dwell-times, keeping the same plan, were manually set to 55 seconds for dwell index
1500mm, 55 seconds for dwell index 1495mm, 45 seconds for dwell index 1490mm, and 45
seconds for dwell index 1485mm for both ovoids. This dwell-time combination results in a
maximum dwell-time weighting difference for this set is thus 5%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.20. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 26.6% of the
comparison points are within +/- 2% or +/- 2mm.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.21a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 99.2% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and ovoid-based corrected TG-43 plan.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.21b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. Again, there are
no appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.20: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield
(red) vs. TG-43 calculations for a source in water (blue). Maximum adjacent dwelltime gradient is 5%. Both ovoids are illustrated to show the plane and size of the
ovoids. Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).
Quantitatively, 26.6% of the comparison points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.21: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible Fletcher
ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time gradient
is 5%. Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using (a)
ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position indices:
1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 99.2% and 100% of the comparison points are within +/- 2% or
+/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.
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3.3.1.2 Dwell-Time Gradient of 10%
The dwell-times were manually set to 60 seconds for dwell index 1500mm, 60 seconds
for dwell index 1495mm, 40 seconds for dwell index 1490mm, and 40 seconds for dwell index
1485mm for both ovoids. The maximum dwell-time gradient for this combination is 10%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.22. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 30.1% of the
comparison points are within +/- 2% or +/- 2mm.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.23a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 96.3% of the comparison points are within +/- 2% or +/- 2mm.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.23b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and source-based corrected TG-43 plan.
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Figure 3.22: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield
(red) vs. TG-43 calculations for a source in water (blue). Maximum adjacent dwelltime gradient is 10%. Both ovoids are illustrated to show the plane and size of the
ovoids. Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).
Quantitatively, 30.1% of the comparison points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.23(a-b): Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible
Fletcher ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time
gradient is 10%. Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated
using (a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwellposition indices: 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 96.3% and 100% of the comparison points are
within +/- 2% or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.
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3.3.1.2 Dwell-Time Gradient of 15%
The dwell-times, keeping the same plan, were manually set to 5 seconds for dwell index
1500mm, 7.5 seconds for dwell index 1495mm, 45 seconds for dwell index 1490mm, and 67.5
seconds for dwell index 1485mm for both ovoids. The maximum dwell-time gradient for this
combination is 30%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.24. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 34.4% of the
comparison points are within +/- 2% or +/- 2mm.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.25a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 85.9% of the comparison points are within +/- 2% or +/- 2mm.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.25b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and source-based corrected TG-43 plan.
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Figure 3.24: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield
(red) vs. TG-43 calculations for a source in water (blue). Maximum adjacent dwelltime gradient is 15%. Both ovoids are illustrated to show the plane and size of the
ovoids. Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).
Quantitatively, 34.4% of the comparison points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.25: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a CT modified CT-MR compatible Fletcher
ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time gradient
is 15%. Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using
(a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position
indices: 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 85.9% and 100% of the comparison points are within +/- 2%
or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.
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3.3.1.2 Dwell-Time Gradient of 30%
The dwell-times, keeping the same plan, were manually set to 5 seconds for dwell index
1500mm, 7.5 seconds for dwell index 1495mm, 45 seconds for dwell index 1490mm, and 67.5
seconds for dwell index 1485mm for both ovoids. The maximum dwell-time weighting
difference for this combination is 30%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.26. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 66.9% of the
comparison points are within +/- 2% or +/- 2mm.
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.27a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 34.2% of the comparison points are within +/- 2% or +/- 2mm.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.27b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and source-based corrected TG-43 plan.
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Figure 3.26: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a
modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield (red)
vs. TG-43 calculations for a source in water (blue). Maximum adjacent dwell-time
gradient is 30%. Both ovoids are illustrated to show the plane and size of the ovoids.
Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four per ovoid,
dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively,
66.9% of the comparison points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.27: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible Fletcher
ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time gradient
is 30%. Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated using
(a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwell-position
indices: 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 34.2% and 100% of the comparison points are within
+/- 2% or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.
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3.3.1.3 Dwell-time Gradient of 60%
The dwell-times, keeping the same plan, were changed to 5 seconds for dwell index
1500mm, 5 seconds for dwell index 1495mm, 35 seconds for dwell index 1490mm, and 155
seconds for dwell index 1485mm for the left ovoid. The right ovoid dwell-times are the same as
the left, but the order of the dwell indices is flipped. The maximum dwell-time gradient for this
combination is 60%.
Comparison of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology is shown in Figure 3.28. The CT-MR compatible Fletcher ovoid illustration is to
convey the size and placement of the ovoid pair. Although the plane bisects the source dwellpositions, and the source is only at a single location at any given time, the source is not
illustrated. Observed in this figure are the qualitative differences in dose due to the perturbing
effects of the ovoids accounted for in MC simulations (dashed red lines) and unaccounted for in
TG-43 calculations (solid blue line) for a single 2D plane. Quantitatively, 10.5% of the
comparison points are within +/- 2% or +/- 2mm. .
Comparisons of MC-simulated isodose distributions and isodoses calculated using TG-43
methodology that has been corrected using an ovoid-based correction factor is shown in Figure
3.29a. Observed in this figure are the qualitative differences in dose for MC simulations (dashed
red lines) and ovoid-based corrected TG-43 plan (solid blue line) for a single 2D plane.
Quantitatively, 56.8% of the comparison points are within +/- 2% or +/- 2mm.
Next, comparisons for MC-simulated isodose distributions and isodoses calculated using
TG-43 methodology that has been corrected using a source-based correction factor is shown in
Figures 3.29b. This figure illustrates the qualitative differences in dose for MC simulations
(dashed red lines) and source-based corrected TG-43 plan (solid blue line) for a single 2D plane.
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Quantitatively, 100% of the comparison points are within +/- 2% or +/- 2mm. There are no
appreciable differences between the MC simulation and source-based corrected TG-43 plan.

Figure 3.28: Comparison of MC simulation of a mHDR v2 Ir-192 source contained in
a modified CT-MR compatible Fletcher ovoid applicator to include a high-Z shield
(red) vs. TG-43 calculations for a source in water (blue). Maximum adjacent dwelltime gradient is 60%. Both ovoids are illustrated to show the plane and size of the
ovoids. Shown here are absolute dose comparisons, in Gy, for 8 dwell-positions (four
per ovoid, dwell-position indices of 1500, 1495, 1490, 1485 mm for each ovoid).
Quantitatively, 10.5% of the comparison points are within +/- 2% or +/- 2mm.
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(a)
(b)
Figure 3.29(a-b): Comparison of MC simulation of a mHDR v2 Ir-192 source contained in a modified CT-MR compatible
Fletcher ovoid applicator to include high-Z shield vs. TG-43 corrected plans of a source in water. Maximum adjacent dwell-time
gradient is 60%. Shown here are 2D planes bisecting the ovoid pair comparing full MC calculations (red) and isodoses calculated
using (a) ovoid-based and (b) source-based corrected TG-43 plan (blue), in Gy, for 8 dwell-positions (four per ovoid, dwellposition indices: 1500, 1495, 1490, 1485 mm for each ovoid). Quantitatively, 56.8% and 100% of the comparison points are
within +/- 2% or +/- 2mm for the ovoid-based and source-based corrected TG-43 plan, respectively.
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3.3.3 Summary of Results
Table 3.1 lists the agreement (percent dose and DTA) for comparisons of MC simulated
and TG-43 calculated 3D dose distributions utilizing a comparison dose cut-off of 50 cGy
isodose line. These results indicate that a TG-43 isodose calculation of a mHDR v2 Ir-192
source in water agrees within the uncertainty of the MC simulation for any combination of
dwell-time gradients. Although ovoid- and source- based corrected plans had better agreement
than TG-43 calculations with full MC datasets, the TG-43 calculations agree within the MC
uncertainty. For every dwell-time combination, the source- based corrected plan agreed 100%
with the full MC dataset.
Table 3.1: Agreement of MC simulation with TG-43 data set, Ovoid-correction plan, and
Source-correction plan. Agreement metric: 2% or 2mm.
∇
0%

30%

60%

70%

MC versus:
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan

Agreement
(2%/2mm)
99.8%
100%
100%
99.7%
99.9%
100%
99.0%
99.7%
100%
99.6%
99.9%
100%

Table 3.2 lists the agreement for comparisons between the simulations from the modified
MC model which includes high-Z inhomogeneities. This high-Z shield alteration to the CT-MR
compatible Fletcher ovoid model was to test the robustness of the correction schemes for dose
distributions that were relatively different to TG-43 dose calculations of a single source in water.
This modification was studied since the MC simulations of a single source within the CT-MR
compatible Fletcher ovoid agreed within the MC uncertainty with the TG-43 calculations of a
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source in water. As expected, there was not a single MC simulation that agreed within criteria
when compared to the full MC dataset. There is relatively higher agreement with the plan
having a ∇dt equal to 30. This can be a contributed to the dwell-time combination being utilized
for this comparison. This plan has the highest dwell-times at the dwell-positions farther from the
shields and relatively low dwell-times near the shields. The source- based corrected plans agreed
100% with the full MC simulations. Agreement was not affected on the difference between the
TG-43 calculations compared to MC. It seems as if the limiting factor for agreement was due to
the maximum ∇dt. Once the maximum ∇dt was above 10%, the ovoid- based correction scheme
began to fail.
Table 3.2: Agreement of modified MC model simulation with TG-43 data set, Ovoid-correction
plan, and Source-correction plan. Agreement metric: 2% or 2mm.
∇

0%

5%

10%

15%

30%

60%

MC versus:

Agreement
(2%/2mm)

TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan
TG-43
Ovoid-Correction plan
Source-Correction plan

13.2%
100%
100%
26.6%
99.2%
100%
30.1%
96.3%
100%
34.4%
85.9%
100%
67.0%
59.1%
100%
10.5%
56.8%
100%
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3.4 Discussions
Dose perturbations resulting from the ICBT CT-MR compatible Fletcher applicator set
were relatively small and agreed to TG-43 calculations for a source in water within the
uncertainty of the MC simulations (>99% points within +/-2% dose or 2mm DTA). This is due
to the main ovoid heterogeneity being polyphenylsulfone with a density very similar to water.
This makes the entire MC model fairly homogeneous. Thus, a correction scheme is not
necessary.
The “shielded” ovoid applicator set did not agree to TG-43 calculations for a source in
water. This MC model was introduced to test the robustness of both correction schemes (ovoidor source-based). Dose perturbations were due to a significant ovoid heterogeneity. The
tungsten shield in this study is relatively larger than clinically-available ovoid shields.
Correction factors were applied to TPS exported plans by developing software written in Matlab.
Once the DICOM compatible files were compiled into a Matlab format, the software extracted
treatment parameters such as dwell-times, dwell-coordinates, source activity, dose grid size, and
dose grid axis indexes. These parameters were then applied to the MC simulation to generate an
equivalent treatment plan.
Plans generated by Oncentra TPS with a maximum dwell-time gradient less than 10%
can be corrected utilizing either the ovoid-based or source-based correction methods to agree
with full simulated Monte Carlo datasets to within +/- 2% or +/- 2mm DTA. Although, dwelltime combinations utilized in this study with a maximum dwell-time gradient above 10% is a
threshold for the ovoid- based correction scheme to correct the TG-43 calculation. The sourcebased correction method consistently results in 100% agreement between a corrected plan and
the equivalent MC generated plan.
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For brachytherapy plans with equivalent dwell-times, as typically found with plans
generated using the Manchester system, either correction scheme is appropriate. Treatment plans
that generate a “patient” specific dose distribution, rather than the dose distribution inherent to
the tandem and ovoid applicator (i.e. pear shape), to cover the disease need to utilize the sourcebased correction method. A “patient” specific dose distribution is commonly generated utilizing
the GEC ESTRO dose specification.
It should be noted that this correction scheme requires a CT dataset that does not contain
high-Z artifacts. This criterion is made possible only with Nucletron’s Anatomically Adaptive
Applicator. Currently, investigations are being made that by using a MVCT (as opposed to a
kVCT) scan, high-Z artifacts can be reduced significantly.
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Chapter 4 Conclusions
4.1 Summary of Results
This study was able to confirm the absolute dose distributions calculated by MCNPX for
a CT-MR compatible ICBT applicator. We demonstrated that our MC modeling of a paired
ovoid set (without surrogate shield) is accurate and robust enough to simulate dose distributions
with sufficient accuracy within the context of this study.
Ovoid- and source-based correction factors were created for a clinically utilized ovoid
paired set (with and without shield surrogate) for four dwell positions per ovoid with a 5mm
step-size. In all, there were two ovoid- based correction factors for each ovoid (left and right)
and eight source- based correction factors for each individual dwell positions.
Plans calculated utilizing Oncentra were corrected to include dose perturbations from the
“shielded” ovoid set. The ovoid- based correction factors improved TG-43 calculated plans with
maximum dwell-time gradients of less than 10%. The source- based correction scheme
consistently generated results that agreed 100% with the full MC simulation.

4.2 Evaluation of Hypothesis
“A 3D Monte Carlo-simulated dose distribution of the ovoid contribution to a cervical
intracavitary brachytherapy (ICBT) treatment administered via Nucletron’s Fletcher CT-MR
ovoid applicator (Nucletron Corporation, Veenendaal, The Netherlands), modeled with and
without a rectal shield surrogate, will agree, within criteria, with the dose distribution resulting
from an equivalent treatment calculated using AAPM Task Group-43 (TG-43) methodology
when corrected for heterogeneities using pre-calculated MC correction factors applied (a) to
individual source dwell-positions and (b) individual ovoids acting as multi-source surrogates for
varying adjacent dwell-time gradients (∇dt). Criteria are defined as agreement within +/- 2% or
+/- 2 mm distance-to-agreement.”
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The results of this research support part of the hypothesis that applicator correction
factors calculated for individual source, as opposed to ovoid, positions are required to predict
intracavitary brachytherapy dose distributions that agree with Monte Carlo simulations to within
2% dose or 2mm DTA for dwell-time gradients greater than 10%. However, for dwell-time
gradients below 10%, either correction scheme (ovoid- or source- based) will result in a dose
distribution that agrees within criteria.

4.3 Future Work
Since dose grids larger than 7x7x7cm (1mm3 resolution) are too large to process using the
Gridconv auxiliary MCNPX program [11], another method should be sought out to convert the
MC output to a format that can be integrated into the process utilized in this study. A larger MC
dose grid on the order of 16cm3 should be processed in order to account for translation of the
sources in a 10x10x10cm3 dose grid. This will allow for the corrected dose distribution to be
added to the tandem contribution of the ICBT procedure without losing dose information beyond
the distal end of the tandem.
The method presented in this study utilizing MATLAB does not allow for a multi-frame
DICOM file to be generated. Another strategy should be sought out so that the corrected dose
distribution can be imported to Oncentra in DICOM format for plan analysis.
Nucletron’s next generation TPS utilizes Collapsed Cone Convolution to calculate
patient-specific dose distributions. Although the CCC algorithm cannot handle large
perturbations in dose due to high-Z heterogeneities like those introduced by intra-ovoid
shielding. The methods presented in this work can be used to correct these dose distributions for
the effect of ovoid shielding, thus providing an accurate representation of dose delivered to a
patient undergoing ICBT.
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Appendix 1 Process Digitized Film (.tiff images) and Calculate
Standard Deviation
% This processes .tiff images and calculates the average standard deviation
% and the standard deviation of the standard deviation...
% Input: 3 processed (scanned) RCF datasets as .tiff images
%Import films
D1 = double(imread('disease1001.tif'));
D2 = double(imread('disease2001.tif'));
D3 = double(imread('disease3001.tif'));
%Red channel
gFilmOne1=D1(:,:,1);
gFilmOne2=D2(:,:,1);
gFilmOne3=D3(:,:,1);
%Smooth
gFilmOne1=wiener2(gFilmOne1);
gFilmOne2=wiener2(gFilmOne2);
gFilmOne3=wiener2(gFilmOne3);
%Crop.. index specified by location on flat-bed scanner
gFilmOne1crop=gFilmOne1(150:580,150:580);
gFilmOne2crop=gFilmOne2(150:580,150:580);
gFilmOne3crop=gFilmOne3(150:580,150:580);
%Resolution
info = imfinfo('disease1001.tif');
xresolution = info.XResolution;
yresolution = info.YResolution;
xres_setting = (2.54)/xresolution;
yres_setting = (2.54)/yresolution;
%Interpolate to 1mm^3
[rowsfilm colsfilm] = size(gFilmOne1crop);
xx = 0 : xres_setting : xres_setting * (rowsfilm - 1);
yy = 0 : yres_setting : yres_setting * (colsfilm - 1);
xend = floor(xres_setting * (rowsfilm - 1));
yend = floor(yres_setting * (colsfilm - 1));
XI = 0:0.1:xend;
YI = 0:0.1:yend;
%Film 1
for i = 1:(11*10+1);
for j = 1:(11*10+1);
iFilmOne(j,i) = interp2(yy,xx,gFilmOne1crop,XI(i),YI(j),'*linear');
end
end;
%Crop to 101 x 101 dose grid to match MC
gFilmOne1_interp = iFilmOne(1:101,11:111);
%Convert scanner values to absolute dose (calibration curve)
gF1 = arrayfun(@(x) 0.000000021448218*x.^2 - 0.002274568204140*x +...
61.167641732761900, gFilmOne1_interp);
%Film 2
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for i = 1:(11*10+1);
for j = 1:(11*10+1);
iFilmOne(j,i) = interp2(yy,xx,gFilmOne2crop,XI(i),YI(j),'*linear');
end
end;
%Crop to 101 x 101 dose grid to match MC
gFilmOne2_interp = iFilmOne(1:101,11:111);
%Convert scanner values to absolute dose (calibration curve)
gF2 = arrayfun(@(x) 0.000000021448218*x.^2 - 0.002274568204140*x +...
61.167641732761900, gFilmOne2_interp);
%Film 3
for i = 1:(11*10+1);
for j = 1:(11*10+1);
iFilmOne(j,i) = interp2(yy,xx,gFilmOne3crop,XI(i),YI(j),'*linear');
end
end;
%Crop to 101 x 101 dose grid to match MC
gFilmOne3_interp = iFilmOne(1:101,11:111);
%Convert scanner values to absolute dose (calibration curve)
gF3 = arrayfun(@(x) 0.000000021448218*x.^2 - 0.002274568204140*x +...
61.167641732761900, gFilmOne3_interp);
%average data sets
mean=(gF1+gF2+gF3)/3;
%Number of .tiff images
N=3;
sigma_map=zeros(101,101);
count=0;
%calculate sigma
for i = 1:101,
for j = 1:101,
x_mean=mean(i,j);
x_i_1 = gF1(i,j);
x_i_2 = gF2(i,j);
x_i_3 = gF3(i,j);
l = (x_i_1 - x_mean)^2;
m = (x_i_2 - x_mean)^2;
n = (x_i_3 - x_mean)^2;
numerator = l+m+n;
sigma_map(i,j)= sqrt(numerator/(N-1));
count = count+sigma_map(i,j);
end
end
sigma_map_mean = (sigma_map/sqrt(N));
%standard deviation of the average standard deviation
average_of_sigmas = count/(101*101);
summation=0;
for i = 1:101,
for j = 1:101,
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x_i=sigma_map_mean(i,j);
x_mean = average_of_sigmas;
difference=(x_i - x_mean)^2;
summation = summation+difference;
end
end
standard_deviation_of_sigma = sqrt(summation/(101*101));
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Appendix 2 Compile Dose Grid from a RD DICOM File
%Input:RD_DICOM (.dcm extension) from TPS
%DICOM scales the dose grid down, obtain scaling factor using dicominfo to
%scale back into actual values
factor = dicominfo('filename.dcm');
dosegridscaling = double(factor.DoseGridScaling);
%Dose grid dimensions
frames = factor.NumberOfFrames;
rows = factor.Rows;
columns = factor.Columns;
%Create a matrix the same size as DICOM dose grid
Empty = double(zeros(frames,rows,columns));
%Compile all 2D frames to develop 3D dose grid
for i = 1:frames,
b = double(dicomread('filename.dcm','frames',i));
Empty(:,i,:) = b(101:-1:1,:,:) * dosegridscaling;
end;
%Name Dose grid, and save it as .mat file
RENAME = Empty;
save('RENAME','RENAME');
%end
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Appendix 3 Dose Tolerance and Distance to Agreement Algorithm
% Calculates the percentage of points that agree within percent tolerance
% of absolute dose or able to locate a valid point within specified distance.
% Input: 2 matrices the same size (measured, calculated)
% Resolution must be 1mm^3
% DTA specified in mm, Dose tolerance specified in percent (i.e. 2 %)
% Low limit threshold specified in same unit as dose grid values
measured = compare1;
calculated = compare2;
DTA = 3;
tolerance = 3;
limit = 3;
% Pass/fail matrix, same size as input
% Begins with all 10s, when a point passes, replaces it with value of 1.
% (i.e. points above 1 fail)
size1 = size(measured);
passfail = zeros(size1(1),size1(2),size1(3));
passfail = passfail + 10;
% tallies = 0 to begin
passtally = 0;
falsetally = 0;
totaltally = 0;
highlimit = 0;
lowlimit = 0;
blackbox = 0;
%Begin DTA algorithm
for i = 1:size1(1);
for j = 1:size1(2);
for k = 1:size1(3);
% Condition statements to kickout points below limit threshold,
% above high limit threshold, or within a blackbox (for this study,
% non-relative clinical points were set to negative values)
if calculated(i,j,k) <= limit && calculated(i,j,k) >= 0,
lowlimit = lowlimit + 1;
else
if measured(i,j,k) <= limit && measured(i,j,k) >= 0,
lowlimit = lowlimit + 1;
else
if calculated(i,j,k) > 15 || measured(i,j,k) > 15 ,
highlimit = highlimit + 1;
else
if calculated(i,j,k) <= 0 || measured(i,j,k) <= 0,
blackbox = blackbox + 1;
else
% If point does not fall within condition statements above, it is used as a
% valid comparison point for agreement analysis.
totaltally = totaltally + 1;
86

% Check if corresponding pixel is within tolerance. If sufficient, no more
% comparisons are needed and the process starts over, otherwise.. continue
if abs((((calculated (i, j, k) - measured(i, j, k)))/(measured(i, j, k))*100)) <= tolerance,
passfail(i,j,k) = 1;
passtally = passtally + 1;
else
%Begin "Neighborhood" search for value within tolerance
% Define indexes that construct neighborhood
startrow = i - DTA;
endrow = i + DTA;
startcol = j - DTA;
endcol = j + DTA;
startheight = k - DTA;
endheight = k + DTA;
% Boundary fix
if startrow <= 0, startrow = i; end
if endrow > size1(1), endrow = size1(1); end
if startcol <= 0, startcol = j; end
if endcol > size1(2), endcol = size1(2); end
if startheight <= 0, startheight = k; end
if endheight > size1(3), endheight = size1(3); end
%Neighborhood of pixels of measured with respect to calc(i, j, k).
neighborhood = measured(startrow:endrow,startcol:endcol,startheight:endheight);
numrows = endrow - startrow + 1;
numcols = endcol - startcol + 1;
numheight = endheight - startheight + 1;
% Minigrid is small version of pass/fail conditions
% Caution, kickout conditions are not evaluated for neighborhood search
minigrid = zeros(numrows,numcols,numheight);
Dosediff_criterion = zeros(numrows,numcols,numheight);
% Search neighborhood for a point that passes both criterions
for r = 1:numrows;
for s = 1:numcols;
for t = 1:numheight;
calcpt = calculated(i,j,k);
%Step pixels from end to start.
rowstep = (r - (DTA + 1));
colstep = (s - (DTA + 1));
heightstep = (t - (DTA + 1));
newrow = i - rowstep;
newcol = j - colstep;
newheight = k - heightstep;
%Check distance of neighborhood pixel.
distance = sqrt(((i-newrow)^2 + (j-newcol)^2 + (k-newheight)^2));
%Check if corresponding pixel is within tolerance.
Dosediff_criterion(r,s,t) = abs((((calcpt - neighborhood(r,s,t))...
/(neighborhood(r,s,t)))*100));
if (distance <= DTA) && (Dosediff_criterion(r,s,t) <= tolerance),
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minigrid(r,s,t) = 1;
else
minigrid(r,s,t) = 5;
end;
end;
end;
end;
%End "Neighborhood" search for value within tolerance
passfail(i, j, k) = min(min(min(minigrid)));
%If passfail point passes, add 1 to passtally, if not
%add one to falsetally
if passfail(i,j,k) <= 1,
passtally = passtally + 1;
else
falsetally = falsetally + 1;
end;
end;
% End kickout 'if' conditional statements
end;
end;
end;
end;
% End i,j,k loops
end;
end;
end;
passrate = floor((passtally/(passtally+falsetally))*100);
%Send passrate to command window
passrate
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Appendix 4 Define Plan Parameters from RP, RD DICOM Files
% for a Plan Consisting of Two Ovoids with 6 out of 8 Active Dwell-Positions
%Dig for variables to build MC dose distribution
infoRP = dicominfo('RPT.dcm');
infoRD = dicominfo('RDT.dcm');
%Find right ovoid source coordinates
coordinateRT1 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy...
ControlPointSequence.Item_2.ControlPoint3DPosition;
coordinateRT2 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy...
ControlPointSequence.Item_4.ControlPoint3DPosition;
coordinateRT3 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy...
ControlPointSequence.Item_6.ControlPoint3DPosition;
%listed as x, y, z
R1500 = [ (coordinateRT1(3)) (coordinateRT1(1)) -(coordinateRT1(2)) ];
R1495 = [ (coordinateRT2(3)) (coordinateRT2(1)) -(coordinateRT2(2)) ];
R1490 = [ (coordinateRT3(3)) (coordinateRT3(1)) -(coordinateRT3(2)) ];
%left
coordinateLT1 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy...
ControlPointSequence.Item_2.ControlPoint3DPosition;
coordinateLT2 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy...
ControlPointSequence.Item_4.ControlPoint3DPosition;
coordinateLT3 = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy...
ControlPointSequence.Item_6.ControlPoint3DPosition;
L1500 = [ (coordinateLT1(3)) (coordinateLT1(1)) -(coordinateLT1(2)) ];
L1495 = [ (coordinateLT2(3)) (coordinateLT2(1)) -(coordinateLT2(2)) ];
L1490 = [ (coordinateLT3(3)) (coordinateLT3(1)) -(coordinateLT3(2)) ];
%Decimal spot
R1500x = sign(coordinateRT1(3))*(abs(coordinateRT1(3)) - abs(fix(coordinateRT1(3))));
R1500y = sign(coordinateRT1(1))*(abs(coordinateRT1(1)) - abs(fix(coordinateRT1(1))));
R1500z = -sign(coordinateRT1(2))*(abs(coordinateRT1(2)) - abs(fix(coordinateRT1(2))));
R1495x = sign(coordinateRT2(3))*(abs(coordinateRT2(3)) - abs(fix(coordinateRT2(3))));
R1495y = sign(coordinateRT2(1))*(abs(coordinateRT2(1)) - abs(fix(coordinateRT2(1))));
R1495z = -sign(coordinateRT2(2))*(abs(coordinateRT2(2)) - abs(fix(coordinateRT2(2))));
R1490x = sign(coordinateRT3(3))*(abs(coordinateRT3(3)) - abs(fix(coordinateRT3(3))));
R1490y = sign(coordinateRT3(1))*(abs(coordinateRT3(1)) - abs(fix(coordinateRT3(1))));
R1490z = -sign(coordinateRT3(2))*(abs(coordinateRT3(2)) - abs(fix(coordinateRT3(2))));
%left
L1500x = sign(coordinateLT1(3))*(abs(coordinateLT1(3)) - abs(fix(coordinateLT1(3))));
L1500y = sign(coordinateLT1(1))*(abs(coordinateLT1(1)) - abs(fix(coordinateLT1(1))));
L1500z = sign(coordinateLT1(2))*(abs(coordinateLT1(2)) - abs(fix(coordinateLT1(2))));
L1495x = sign(coordinateLT2(3))*(abs(coordinateLT2(3)) - abs(fix(coordinateLT2(3))));
L1495y = sign(coordinateLT2(1))*(abs(coordinateLT2(1)) - abs(fix(coordinateLT2(1))));
L1495z = sign(coordinateLT2(2))*(abs(coordinateLT2(2)) - abs(fix(coordinateLT2(2))));
L1490x = sign(coordinateLT3(3))*(abs(coordinateLT3(3)) - abs(fix(coordinateLT3(3))));
L1490y = sign(coordinateLT3(1))*(abs(coordinateLT3(1)) - abs(fix(coordinateLT3(1))));
L1490z = sign(coordinateLT3(2))*(abs(coordinateLT3(2)) - abs(fix(coordinateLT3(2))));
%Adjust to tenths of a millimeter
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R1500z = R1500z/10;
R1495z = R1495z/10;
R1490z = R1490z/10;
L1500z = L1500z/10;
L1495z = L1495z/10;
L1490z = L1490z/10;
R1500y = R1500y/10;
R1495y = R1495y/10;
R1490y = R1490y/10;
L1500y = L1500y/10;
L1495y = L1495y/10;
L1490y = L1490y/10;
R1500x = R1500x/10;
R1495x = R1495x/10;
R1490x = R1490x/10;
L1500x = L1500x/10;
L1495x = L1495x/10;
L1490x = L1490x/10;
%source activity given as air kerma rate.
activity = infoRP.SourceSequence.Item_1.ReferenceAirKermaRate;
% Partial dwell-time weights..
% Subtract--> BrachyControlPointSequence.Item_y (even# - odd#)
part1500R = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy...
ControlPointSequence.Item_2.CumulativeTimeWeight)-(infoRP.ApplicationSetup...
Sequence.Item_1.ChannelSequence.Item_5.BrachyControlPointSequence.Item_1.Cumu...
lativeTimeWeight);
part1495R = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy...
ControlPointSequence.Item_4.CumulativeTimeWeight)-(infoRP.ApplicationSetup...
Sequence.Item_1.ChannelSequence.Item_5.BrachyControlPointSequence.Item_3.Cumu...
lativeTimeWeight);
part1490R = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Brachy...
ControlPointSequence.Item_6.CumulativeTimeWeight)-(infoRP.ApplicationSetup...
Sequence.Item_1.ChannelSequence.Item_5.BrachyControlPointSequence.Item_5.Cumu...
lativeTimeWeight);
%total time weight
finalR = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.FinalCumu...
lativeTimeWeight;
%Total dwell-time
channeltimeR = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_5.Chan...
nelTotalTime;
%Calculate dwell-time
dwelltime1500R = double((part1500R)/(finalR)*(channeltimeR));
dwelltime1495R = double((part1495R)/(finalR)*(channeltimeR));
dwelltime1490R = double((part1490R)/(finalR)*(channeltimeR));
%LOvoid,difference x--> infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_x
part1500L = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy...
ControlPointSequence.Item_2.CumulativeTimeWeight)-(infoRP.ApplicationSetup...
Sequence.Item_1.ChannelSequence.Item_4.BrachyControlPointSequence.Item_1.Cumu...
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lativeTimeWeight);
part1495L = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy...
ControlPointSequence.Item_4.CumulativeTimeWeight)-(infoRP.ApplicationSetup...
Sequence.Item_1.ChannelSequence.Item_4.BrachyControlPointSequence.Item_3.Cumu...
lativeTimeWeight);
part1490L = (infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Brachy...
ControlPointSequence.Item_6.CumulativeTimeWeight)-(infoRP.ApplicationSetup...
Sequence.Item_1.ChannelSequence.Item_4.BrachyControlPointSequence.Item_5.Cumu...
lativeTimeWeight);
%total time weight
finalL = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.FinalCumu...
lativeTimeWeight;
%Total dwell-time
channeltimeL = infoRP.ApplicationSetupSequence.Item_1.ChannelSequence.Item_4.Chan...
nelTotalTime;
%Calculate dwell-time
dwelltime1500L = double((part1500L)/(finalL)*(channeltimeL));
dwelltime1495L = double((part1495L)/(finalL)*(channeltimeL));
dwelltime1490L = double((part1490L)/(finalL)*(channeltimeL));
%Calculate the MC conversion factor for each dwell-position
%Rotation parameters searches RD DICOM
%x,y,z unit vectors along primary axis
x = [1;0;0];
y = [0;1;0];
z = [0;0;1];
array = infoRD.GridFrameOffsetVector;
checkarray = array';
dimension = (infoRD.ImagePositionPatient);
DCMframes = infoRD.NumberOfFrames;
DCMrows = infoRD.Rows;
DCMcolumns = infoRD.Columns;
% Subtract coordinates to get a vector originating from first and ending at
% the second. Results in a vector originating from (0, 0, 0) to second
% dwell coordinate (should be approximately 5mm in length)
differenceR1 = R1490 - R1495;
%Vector in the xy plane
xycalc = [differenceR1(1); differenceR1(2); 0];
%Use geometry to solve for angles to orient seeds (This just solves for the
%angle in the dot product of two vectors)
zangleR = ((-acosd((dot(differenceR1,z))/(norm(z)*norm(differenceR1)))));
xangleR = acosd((dot(xycalc,x))/(norm(x)*norm(xycalc)));
yangleR = acosd((dot(xycalc,y))/(norm(y)*norm(xycalc)))-90;
%Get unit vector pointing in the direction of the bottom dwells
differenceL1 = L1490 - L1495;
%Vector in the xy plane
xycalc = [differenceL1(1); differenceL1(2); 0];
%Use geometry to solve for angles to orient seeds
zangleL = ((-acosd((dot(differenceL1,z))/(norm(z)*norm(differenceL1)))));
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xangleL = acosd((dot(xycalc,x))/(norm(x)*norm(xycalc)));
yangleL = acosd((dot(xycalc,y))/(norm(y)*norm(xycalc)))-90;
%Parameters to expand small dose grids to larger so that a rotation can be
%applied.
%50 used because grid dimensions were 101x101x101
MCexpand=201;
shift = (MCexpand - 101)/2;
DICOMxgrid = (dimension(1)+50);
DICOMygrid = (dimension(3)+50);
DICOMzgrid = -(dimension(2)+50);
DICOMsetxgrid = dimension(1);
DICOMsetygrid = dimension(3);
DICOMsetzgrid = dimension(2);
%Dose grid indexes for MC dose grid
xgridMC = (0:0.1:0.1*(MCexpand-1))-((MCexpand-1)/20);
ygridMC = (0:0.1:0.1*(MCexpand-1))-((MCexpand-1)/20);
zgridMC = (0:0.1:0.1*(MCexpand-1))-((MCexpand-1)/20);
%Dose grid indexes compiled from DICOM file.. should match above
xgrid = checkarray + dimension(1);
xgrid = xgrid./10;
ygrid = checkarray + dimension(3);
ygrid = ygrid./10;
zgrid = checkarray + dimension(2);
zgrid = zgrid./10;
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Appendix 5 Dose Grid 3D Rotation
%filename (listed in interpolate function) is dose file to be rotated
%Frames, rows, columns defined in DICOM
m = frames;
n = rows;
q = columns;
%Create a list of coordinates from indexes
%e.g. xgridMC = 0:0.1:0.1*101
[X1 Y1 Z1] = meshgrid(xgridMC, ygridMC, zgridMC);
%Rotation matrix for each axis
xaxis = [
1
0
0
;...
0
cosd(xangleL) -sind(xangleL) ;...
0
sind(xangleL) cosd(xangleL) ];
yaxis = [ cosd(yangleL)
0
sind(yangleL) ;...
0
1
0
;...
-sind(yangleL)
0
cosd(yangleL) ];
zaxis = [ cosd(zangleL1) -sind(zangleL1)
0
;...
sind(zangleL1)
cosd(zangleL1)
0
;...
0
0
1
];
%Use matrix multiplication to rotate all at once
rotation_matrix = yaxis*xaxis*zaxis;
%Apply coordinate rotation
XYZ_rotated = (C1)*[X1(:) Y1(:) Z1(:)].';
%Map rotation from old coordinates to new coordinates
newXYZlist = interp3(X1,Y1,Z1,filename,XL1,YL1,ZL1);
%reshape dose grid from blocklist format to a cube
XYZmatrix = reshape(newXYZlist,[m n q]);
XYZmatrix (isnan(XYZmatrix))=0;
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